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Abstract  
 
Chlamydia pneumoniae is an obligate intracellular bacterial pathogen that causes upper 
respiratory infections and pneumonia. The infection in humans may vary from a disease 
with negligible symptoms to a severe pneumonia requiring hospitalization. According to 
serological studies, 50-70% of the adult population is seropositive worldwide, and evidently 
each person can be infected several times during lifetime. Furthermore, the bacterium has 
been associated with several chronic conditions such as asthma, chronic bronchitis and 
chronic coronary heart disease.  
Occurrence of repeated infections indicates that the immunity after Chlamydia infection 
is not completely protective and long-lived. As antimicrobial therapy may not either be 
effective in resolving the infection in the associated chronic conditions, vaccination against 
C. pneumoniae could be an effective strategy for preventing and controlling such infections. 
The experimental animal models to study C. pneumoniae infection have shown that cell-
mediated immunity is necessary for protection against C. pneumoniae in mice. More 
specifically, IFN-γ and CD8+ cells have shown to be important effectors mediating the 
protection suggesting that Th1 type response is essential for protection.  
The purpose of this project was to design vaccine constructs and regimens for studying 
protective immunity in C. pneumoniae mouse model. In order to study antigen specific 
immune responses, we first needed to obtain C. pneumoniae proteins that could be used as 
reagents in immunological assays. However, purification of proteins from C. pneumoniae 
EB is difficult, the main obstacle being its parasitic nature. To overcome this, we chose a 
Bacillus subtilis heterologous protein expression system for production of C. pneumoniae 
proteins and evaluated their immunogenicity in the experimental model for C. pneumoniae 
infection. 
For inducing Th1 type immune responses in mice, we chose DNA immunization and 
viral vector immunization strategies. Naked DNA plasmids or recombinant Semliki Forest 
virus vectors were tested alone or combined in heterologous prime-boost regimen. Two C. 
pneumoniae envelope proteins and the main cytoplasmic chaperone (Hsp60) were chosen 
for evaluation as vaccine candidates.  
In mice, especially C. pneumoniae MOMP expressing vaccines were able to confer 
partial microbiological protection against the pulmonary challenge. All the afore-mentioned 
immunization techniques induced in vaccinated mice systemic humoral and cell-mediated 
responses, measured as serum antibody production, antigen-specific splenocyte proliferation 
and IFN-γ production. However, DNA priming followed by rSFV boosting induced a more 
prominent IFN-γ production after challenge at the site of infection in pulmonary and 
mediastinal cells. The result may suggest that prime-boost method could be beneficial by 
directing the effector-cells to the site of infection and inducing a strong local immune 
response, but also speak in favor of DNA as an adjuvant for Th1 type immunity.  
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1. Review of the literature 
1.1. Vaccines against intracellular microbes 
 
Vaccination has globally had a major impact on reduction of morbidity and mortality 
caused by several bacterial and viral infections. However, there are still diseases like HIV 
and malaria, for which effective vaccines are not available (Gurunathan et al., 2000). The 
requirements for protective immunity in these infections are obviously different from the 
responses that are induced by the current vaccines (Seder and Hill, 2000). Vaccines in 
clinical use usually consist of either killed or attenuated microbes (influenza, pertussis, 
polio, measles, tuberculosis) or subunits of these organisms (Haemophilus influenzae type 
B, Meningococcus A and C, Hepatitis B)(Grandi, 2003). These types of vaccines readily 
induce long-lived humoral immune response as well as cell-mediated response and 
production of protective antibodies has indeed been sufficient against most of the 
aforementioned infections. However, in infections like HIV and malaria, as well as in many 
other infections caused by intracellular microbes, protective immunity depends strongly on 
the action of cell-mediated immunity; i.e. on T lymphocytes that are able to mediate the 
destruction of infected cells and/or the infectious agent residing inside the cell. So far, the 
induction of protective and long-lasting cell-mediated immunity has proven to be a difficult 
task despite of advances in increased understanding of the nature of immune responses. 
1.2. Chlamydiae, common human pathogens 
1.2.1. Chlamydiae 
Chlamydiae are common pathogens that can infect both humans and animals. They have 
diverged from other bacteria very early in bacterial evolution, and their genome degradation 
suggests that they have adapted to intracellular life style for a long time ago (Stephens, 
1999). Chlamydiae are small in size compared to other bacteria, and the obligatory 
intracellular lifestyle first suggested them to be protozoa or viruses, until in late 1960s they 
were proved to belong to bacteria (Stephens, 1999). Chlamydiae are Gram-negative 
bacteria. Their envelope consists of an inner membrane, a periplasmic space, and an outer 
membrane  (Fig. 1). Chlamydial envelope structure differs from that of other gram-negative 
bacteria. Chlamydia has no peptidoglycan in the periplasmic space of its envelope, even 
though it has all the genes required for the synthesis of peptidoglycan. Instead, the rigidity 
of the envelope is based on the cysteine-rich proteins that are integrated into the chlamydial 
outer membrane. Also, the chlamydial truncated LPS is different from the LPS of other 
Gram-negative organisms by its lower endotoxicity. The LPS of C. trachomatis L2 strain 
consists only of a unique 3-deoxy-D-manno-octulosonic acid (KDO) trisaccharide, which is 
linked to a lipid A moiety. Chlamydial lipid A contains five fatty acid chains while there is 
six fatty acid chains in the lipid A structure of the highly active endotoxin of enterobacteria. 
Also, the fatty acid chains are longer in chlamydial lipid A than in enterobacterial lipid A. 
However, the surface exposed KDO trisaccharide of chlamydial LPS is highly  
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Figure 1. An electron microscope picture of an elementary body of Chlamydia pneumoniae 
(courtesy of Laura Mannonen). The most obvious feature is electron dense (black) DNA core. 
Surrounding the cytoplasm is a lipid cytoplasmic membrane, a large periplasmic space and a rigid 
outer envelope.  
 
 
immunogenic, and it is the major genus-specific antigen that is readily recognized by 
humoral immune response. (Rund et al., 1999) 
Chlamydiae have been placed in their own order, Chlamydiales. Characteristic to this 
bacteria order is their unique biphasic developmental cycle, in which Chlamydiae alternate 
between extracellular, infective and metabolically inert form and intracellular, non-
infective, but metabolically active form. (Fields and Hackstadt, 2002) (Fig. 2). At the 
beginning of the cycle, the small (Ø 0.2µm), infectious form of chlamydia, elementary body 
(EB), attaches to the host cell and enters cell within membrane-bound vesicle. Inside the 
vesicle, the bacterium is able to inhibit the phagolysosomal fusion by modifying the nascent 
inclusion membrane. The Chlamydia-containing inclusions become fusogenic with 
sphingomyelin and cholesterol containing exocytic vesicles, and thereby they are 
dissociated from the endocytic pathway (Hackstadt et al., 1997). Within the intact vesicle, 
chlamydia rapidly differentiates to metabolically active form, reticulate body (RB, Ø 1µm) 
and starts replication by binary fission. After multiple divisions inside the vacuole, RBs 
transform to infective EB forms. The genomic DNA condensates with the aid of histone-like 
proteins, and disulfide bridges of bacterial cysteine-rich outer membrane proteins are cross-
linked (Hackstadt, 1999). At the end of this cycle, EBs are released from the host cell in 
order to attach and infect new host cells. The duration of chlamydial developmental cycle in 
cultured cell lines is approximately 48-72 hours. 
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Figure 2. The Chlamydia developmental cycle (modified from (Rottenberg et al., 2002)). 
 
 
The content of the Chlamydiales order is under discussion among researchers in the 
Chlamydia field. Originally, the order was considered to consist of one family, 
Chlamydiaceae that included one genus, Chlamydia. However recently, new chlamydia-like 
organisms have been isolated from e.g. calf and amoebas. The phylogenetic analysis, that 
was done by comparing 16S and 23S rRNA genes of these new organisms and already 
classified species, has suggested that the organisms should be classified into the chlamydial 
order as members of new families (Everett et al., 1999; Meijer et al., 2000; Ossewaarde and 
Meijer, 1999; Rurangirwa et al., 1999). The suggested new families would be 
Parachlamydiaceae, Simkaniaceae and Waddliaceae and each family would consist of one 
or two representatives. On the other hand, as long as the number of new species is small, the 
revision of taxonomy is probably not substantiated. More isolates and information of these 
new organisms are needed. 
According to the analogous phylogenetic analysis of 16S and 23S DNA sequences, the 
family of Chlamydiaceae should also be divided in two genera, Chlamydia and 
Chlamydophila, instead of one genus, Chlamydia. The new genus Chlamydia would 
include more species than the old genus, if some present serovars were classified as new 
species (Everett et al., 1999). This reform has faced strong resistance because the method, 
that is based on the differences in 16S and 23S RNA genes, has been criticized to be 
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improper for speciation (Schachter et al., 2001). The original nomenclature where all 
species are named as Chlamydia in Chlamydiaceae family is still eligible.  
There are four commonly recognized species of Chlamydia: C. trachomatis, C. psittaci, 
C. pneumoniae, and C. pecorum (Morrison and Caldwell, 2002). C. psittaci and C. pecorum 
are primarily animal pathogens infecting mainly birds and ruminants, respectively. Humans 
may also have incidental infections caused by C. psittaci that causes a severe respiratory 
tract infection, psittacosis, in humans. The most well known members of Chlamydiae are 
human genital and ocular pathogen C. trachomatis and respiratory pathogen C. pneumoniae.  
1.2.2. Acute infection caused by C. pneumoniae 
 
C. pneumoniae is one of the most common human pathogens that cause acute infections 
like pneumonia, bronchitis, and pharyngitis. According to the serological studies, 50-70% of 
adult population worldwide is seropositive to C. pneumoniae (Grayston, 1992). As the 
antibody response after natural infection is time-limited (3-5 years), each person can 
evidently become infected several time during his lifetime (Kuo et al., 1995b). 
Respiratory infections caused by C. pneumoniae are also often mild with no symptoms 
or only symptom of extended cough (Miyashita et al., 2003) and in most cases they 
probably remain undiagnosed. For the proper diagnosis of the infectious agent, the 
laboratory tests must be carried out. Unfortunately, to date no standard protocol for C. 
pneumoniae laboratory diagnosis has emerged. The most used method is the serological test, 
micro-immunofluorescence test (MIF) (Wang, 2000; Wang and Grayston, 1970), in which 
the antibody response directed against the surface of formalin-fixed bacteria is detected. The 
method has the advantage of species-specificity. It is technically demanding, and the 
interpretation of the immunological reaction in the assay is subjective and therefore requires 
implicit expertise (Peeling et al., 2000). Commercial enzyme immunoassays (EIAs) for 
detection of C. pneumoniae infections are also available. So far, most of the EIA tests detect 
genus-specific antibodies against lipopolysaccharide (LPS), the major immunogen of 
chlamydia. In some tests, extracted surface structures devoid of LPS are used as antigens in 
order to detect species-specific antibodies. However, the performance of the EIA tests only 
appears to be comparable to that of the MIF test, and best suitable for diagnosing acute 
infections (Ossewaarde et al., 2000). The development of new EIA-assays still needs more 
information of the immunogens of C. pneumoniae expressed during the course of infection. 
C. pneumoniae infection can also be diagnosed by directly detecting the infectious agent, 
bacterial antigens or nucleic acids in patient samples. The specimen should be taken from 
the site of infection: e.g. throat and nasopharynx (swab) or lavage samples from the bronchi 
and alveoli (BAL). Culture of C. pneumoniae is a laborious and insensitive method. For 
culturing, samples must be taken into a specific media containing sucrose in order to 
preserve bacterial infectivity, and the samples should be transported quickly and carefully to 
the specialized research laboratory. The polymerase chain reaction (PCR) tests detecting 
only C. pneumoniae specific nucleic acids have gradually replaced the culturing. This 
method offers greater sensitivity than that of culturing. As the PCR method detects 
microbial DNA instead of alive, infectious microbes from the sample, the preservation and 
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transport of the specimen is less laborious than of the sample for culturing. However, 
although PCR methods are sensitive, the best performance of the tests so far has been shown 
in diagnosing acute infections. When chlamydial infection is successfully diagnosed it can 
be cured with antimicrobial therapy, although cases of possible antibiotic resistance and 
insufficient action have been published (Roblin and Hammerschlag, 1998) and reviewed 
(Boman and Hammerschlag, 2002).  
1.2.3. Chronic infection caused by C. pneumoniae 
 
An asymptomatic and thereby untreated chlamydial infection may become persistent and 
lead to chronic conditions. Also, incomplete immunity after natural infection facilitates 
repeated infections that may exacerbate pathology and lead to chronic conditions. Recurrent 
or persistent genital infections with C. trachomatis may result in salpingitis, pelvic 
inflammatory disease (PID), scarring of fallobian tubes, and lead insidiously to infertility 
(Schachter, 1999). Even more importantly, in many developing countries certain serotypes 
of C. trachomatis are also involved in conjunctivitis. Repeated ocular infections may lead to 
scarring of follicular conjunctiva and cause trachoma, which today still is worlds leading 
cause of infectious blindness (Schachter, 1999). 
The association of C. pneumoniae with chronic human diseases was first shown in 
seroepidemiological studies, which demonstrated the association of antibodies to C. 
pneumoniae with acute myocardial infarction (Saikku et al., 1988). Later, the 
seroepidemiological association of the infection with other chronic conditions, such as 
asthma and chronic bronchitis, has been suggested (Hahn et al., 1991). The 
seroepidemiological association of C. pneumoniae with coronary artery disease (CAD) has 
also been supported by detection of either antigens by immunocytochemistry (ICC) or 
nucleic acids of the organism by PCR in the affected tissues (Kuo et al., 1993a; Kuo et al., 
1993b; Kuo et al., 1995a). Yet, the timing of C. pneumoniae infection and development of 
arteriosclerosis is poorly understood (Danesh et al., 1997; Mahony and Coombes, 2001). 
The diagnosis of an acute C. pneumoniae infection is demanding, but it is even more 
challenging in the case of diagnosing chronic condition. In chronic infections, the amount of 
bacteria in the infected tissue may be very low, or the site of infection is unreachable for 
sampling (e.g. vessel wall). A combination of two different tests, PCR and serological tests 
is often adapted to the diagnosis of chronic chlamydial infections. Usually, inadequate 
samples of the site of the infection, or the difficulty to interprete the meaning of steady-state 
levels of C. pneumoniae specific antibodies hampers the reliable diagnosis (Boman and 
Hammerschlag, 2002).  
Although acute chlamydial infections are curable with antibiotics, the antimicrobial 
therapy, used in treatment of acute infections, may not be effective in resolving the infection 
in the associated chronic conditions (Fong et al., 2002a; Rothstein et al., 2001). Therefore, 
vaccination has suggested being an effective strategy for prevention and also controlling the 
chronic chlamydial infection.  
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1.3. Vaccination against C. pneumoniae 
1.3.1. History of Chlamydial vaccine 
 
The first chlamydial vaccines were developed to protect against trachoma, a blinding 
disease due to certain serotypes of C. trachomatis. In the 1960s and 1970s, animals and 
humans were vaccinated either with live or killed C. trachomatis bacteria. The observed 
protection varied from reduced pathology, lowered disease incidence and shortened course 
of infection to no effect (reviewed by (Rank, 1999)). Probably, the most disappointing effect 
was enhanced disease or enhanced pathology seen in some individuals after challenge 
(Rank, 1999) (Table 1). This has hindered future attempts to use preparations of whole 
chlamydia bacteria to immunize humans against C. trachomatis. However, whole EB 
vaccines have successfully been used to immunize sheep against bovine abortion strain of 
C. psittaci (Rank, 1999) (Table 1). 
 
 
Table 1.  Summary of immunization and challenge experiments against C. trachomatis and C. 
psittaci (modified from (Rank, 1999)). 
 
Immunogen: Live or attenuated bacteria; Chlamydia trachomatis (Ctr) 
Route of 
challenge 
infection 
Route of 
immunization 
Animal 
species Immunogen 
Level of 
protection 
Conjunctival i.m. Human 
Ctr 
(formalinized 
EBs) 
Reduction in disease 
incidence; reduced 
disease; in some 
individuals enhanced 
disease 
-- i.m. Human Ctr (live) 
Short-lived partial 
protection 
Conjunctival i.m. 
Taiwan 
monkey 
Ctr 
(formalinized) 
Variable, enhanced 
pathology in some 
cases 
-- s.c. / i.v. Baboon 
Ctr (heat-
inactivated; 
formalinized; 
UV-inactivated) 
No effect 
-- Oral 
Cynomolgus 
monkey 
Ctr 
(formalinized) 
No effect 
-- Conjunctival Owl monkey Ctr (irradiated) Enhanced disease 
-- i.m. 
Taiwan 
monkey 
Ctr (whole EBs) 
Reduced infection or 
pathology 
-- s.c. / i.v. Baboon Ctr (live) Reduced pathology 
-- Oral 
Cynomolgus 
monkey 
Ctr (live) Reduced pathology 
Intranasal Intrauterine Mouse Ctr MoPn (live) 
Prevention of 
mortality 
Intravaginal Oral Mouse Ctr (live) 
Reduced infection 
length 
-- i.n. Mouse MoPn (live) Prevent infertility 
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-- i.n. /oral / s.c. Mouse 
MoPn (live and 
UV-inactivated) 
Reduced IFU and 
infection length 
Intrabursal i.n. Mouse Ctr MoPn (live) 
Prevention of 
infertility 
Immunogen: Subunit; Chlamydia trachomatis (Ctr) 
Route of 
challenge 
infection 
Route of 
immunization 
Animal 
species Immunogen 
Level of 
protection 
Conjunctival Oral 
Cynomolgus 
monkey 
Ctr partial LPS No effect 
-- Oral/ocular 
Cynomolgus 
monkey 
Ctr octyl-α-D-
glucopyranoside 
(OGP) extracted 
MOMP 
No effect 
-- i.m. 
Cynomolgus 
monkey 
Ctr OGP MOMP 
Reduced infection 
length 
-- 
Conjunctival / 
i.p. / oral 
Cynomolgus 
monkey 
Ctr SDS 
extracted 
MOMP 
Transient reduction in 
pathology 
-- Conjunctival Mouse 
Anti-idiotype / 
chlamydial 
glycolipid 
Reduced IFU and 
disease 
Intrauterine / 
intravaginal 
i.p. /s.c. / i.m. / 
Peyers patch 
Mouse 
Ctr r-MOMP 
fragment 
Reduced infection and 
pathology 
-- i.m. Mouse 
Ctr MOMP 
peptide 
No effect 
-- s.c. Mouse 
Ctr MOMP 
peptide 
No effect 
-- i.v. Mouse 
DC / MoPn 
(heat-killed) 
Reduced IFU and 
infection length; 
reduced hydrosalpinx 
Intrabursal i.d. Mouse 
Ctr (T cell 
peptide) 
Reduced pathology 
-- s.c. Mouse 
MoPn (outer 
membranes) 
Prevention of 
infertility 
-- s.c. Mouse 
MoPn OGP 
MOMP 
No effect 
 
Immunogen: Live or attenuated bacteria; Chlamydia psittaci (Cpsi) 
Route of 
challenge 
infection 
Route of 
immunizatio
n 
Animal 
species Immunogen 
Level of 
protection 
Conjunctival i.m. / s.c. /i.p. Guinea pig 
GPIC EBs 
(formalinized) 
No effect 
-- i.m. Cat 
Cpsi 
(inactivated) 
Reduced pathology/ 
no effect 
-- i.m. Cat Cpsi (live) Reduced pathology 
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-- s.c. Cat Cpsi (live) Reduced pathology 
-- Urethral male Guinea pig GPIC (live) 
Reduced infection 
length  
-- Oral Guinea pig GPIC EBs (live) 
Reduced IFU and 
infection length 
Subcutaneous s.c. Sheep 
Yolk sac 
preparation 
Reduced abortion 
-- s.c. Mouse 
Cpsi 
(attenuated) 
Reduced abortion 
-- s.c. Sheep 
Cpsi 
(inactivated) 
Reduced abortion 
-- s.c. Sheep 
Cpsi 
(inactivated) 
Reduced abortion 
Intraperitoneal i.p. Mouse 
Cpsi 
(attenuated) 
Prevention of 
mortality 
Intravaginal 
Intraurethral 
Oral Guinea pig GPIC EBs (live) No effect 
-- Oral Guinea pig 
GPIC EBs (live 
and UV 
inactivated) 
No effect 
-- Conjunctival Guinea pig GPIC (live) 
Reduced infection 
incidence  
-- Conjunctival Guinea pig GPIC EBs (live) 
Reduced IFU and 
infection length 
-- i.v. / s.c. Guinea pig 
GPIC EBs (live 
and UV 
inactivated) 
Reduced IFU 
-- s.c. Guinea pig 
GPIC (UV-
inactivated) 
Reduced IFU and 
infection length 
Immunogen: Subunit; Chlamydia psittaci (Cpsi) 
Route of 
challenge 
infection 
Route of 
immunizatio
n 
Animal 
species Immunogen 
Level of 
protection 
Subcutaneous s.c. Sheep 
Cpsi outer 
membrane 
Reduced abortion 
Intravaginal s.c. Guinea pig 
GPIC SDS 
Omp2  
No effect 
-- s.c. Guinea pig 
GPIC OGP 
MOMP  
Reduced IFU 
-- s.c. Guinea pig 
GPIC SDS 
MOMP 
No effect 
 
 
Later, the immunization experiments were mainly focusing on the prevention of genital 
Chlamydia infection in various animal models.  In these experiments, animals were usually 
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vaccinated with protein or peptide preparations of outer membrane proteins (MOMP or 
Omp2) of C. trachomatis (Batteiger et al., 1993; Knight et al., 1995; Su et al., 1995; Tuffrey 
et al., 1992). In most cases, the vaccine preparations were immunogenic as they were shown 
to induce antibody production in vaccinated animals, but the vaccines induced only partial 
protection or had no effect against the bacterial challenge. The critical property for protein 
vaccines against C. trachomatis appeared to be the conformation of the protein used for 
immunization. Antigens that were able to induce neutralizing antibodies had better 
possibilities to protect against the subsequent challenge (Batteiger et al., 1993). However, 
although some vaccines were able to induce neutralizing antibodies, the observed protection 
was still only partial and/or temporary. 
Obviously, the incomplete understanding of host immune mechanisms that mediate 
protective immunity against chlamydial infections has hampered the development of an 
efficacious vaccine. At the moment, despite of much research no effective vaccine is yet 
available. Various animal models have also been established to characterize the elements of 
naturally occurring immunity in C. pneumoniae infections. These studies form the basis of 
the present and future immunizations strategies for designing the vaccine against C. 
pneumoniae infection and associated diseases.  
1.3.2. The correlates of protective immunity to C. pneumoniae 
 
Murine models 
Experimental infection models to study acute C. pneumoniae infection in mice have 
been established (Kaukoranta-Tolvanen et al., 1993; Penttila et al., 1998a; Yang et al., 
1993). The intranasal inoculation of C. pneumoniae leads to a self-restricted infection in 
mice, resembling in many respects C. pneumoniae infection in man: this includes kinetics, 
relatively mild symptoms, the developmental of partial protection, and the capacity of 
repeated infections. It has been shown that intranasally inoculated C. pneumoniae infects 
alveolar epithelial cells as well as lung macrophages and peripheral blood mononuclear cells 
(PBMC) in mice (Campbell et al., 2000). Survival inside the circulating 
macrophage/monocytic cells (Moazed et al., 1998; Yang et al., 1995) is probably a 
prerequisite for the systemic dissemination of the bacteria from the respiratory tract to other 
sites of the body, e.g. to the vessel wall. Indeed, in several studies on patients with 
abdominal aortic aneurysm, C. pneumoniae DNA has been detected more often in PBMC of 
these patients than in their healthy controls (Blasi et al., 1999; Maraha et al., 2001).  
To study the role of C. pneumoniae in chronic conditions, i.e. atherogenesis, different 
murine and rabbit models have been used (Blessing et al., 2001; Campbell et al., 2000; Fong 
et al., 1997; Hu et al., 1999; Laitinen et al., 1997; Liuba et al., 2000; Moazed et al., 1996; 
Moazed et al., 1997; Moazed et al., 1999; Muhlestein et al., 1998). These models have 
focused on elucidating the potential contribution of C. pneumoniae infection to the initiation 
and/or progression of atheromatous lesions, but not much is known about immune correlates 
associated with protection from persistent infection and/or pathology. 
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Innate immunity 
The immunological response induced by an infectious agent can be divided into innate 
and acquired immunity. Innate immunity is a non-specific response that involves 
neutrophils and macrophages that immediately phagocytose microbes and kill them already 
at the site of entry. The pathogen is recognized through its conserved structures called 
pathogen associated molecular patterns (PAMP), for example LPS endotoxin, unmethylated 
CpG motifs in bacterial DNA or double-stranded RNA of some viruses (Guermonprez et al., 
2002).  
Epithelial cells at the airways are the first targets for C. pneumoniae invasion. The 
epithelial cells secrete proinflammatory cytokines and chemoattractants in response to 
microbial infection. For example, C. pneumoniae induces the expression and secretion of 
IL-8 cytokine (Yang et al., 2003). This cytokine is a potent activator of neutrophils and 
monocytes that are subsequently recruited to the site of infection. The protective effect of 
innate immunity in early C. pneumoniae infection is mediated by IFN-γ, which is released 
by macrophages and other innate immune cells at the site of infection and results in a 
control of bacterial load (Rottenberg et al., 2000). Also, naive CD8+ T cells provide first 
line defence against C. pneumoniae, and these cells seem to act through cytokine release 
rather than cytotoxicity (Rottenberg et al., 1999). Another role for CD8+ T cells has been 
suggested in determination of the Th1/Th2 type diversity during very early events of 
infection. They could prevent the induction of Th2 type immunity by CD4+ T cells, since 
CD8 deficient mice that were infected with C. pneumoniae showed high IL-10 and IL-4 
expression in their lungs compared to the wild type mice (Rottenberg et al., 1999).  
Another part of innate immune response, in addition to immune effector cells, is the 
dendritic cells (DCs), which are a heterogeneous cell population residing in peripheral 
tissues (e.g. skin, mucosae). In their immature form, they capture pathogens, infected cells, 
dead cells or their products derived thereof (eg. heat shock proteins) by receptor-mediated 
endocytosis. At the same time, the dendritic cells respond to interaction with pathogens 
through various Toll like receptors (TLR) that directly recognize conserved molecular 
patterns of microbes. This course of events matures the DCs to an antigen presenting cell. In 
addition to the pathogen recognition stimulus, the maturation of DCs is influenced by the 
overall cytokine and immunological milieu at the site of infection. This is a result of the 
complex network of proinflammatory cytokines and chemokines that are secreted by the 
infected cells (epithelial, endothelial etc. cells) and immune cells triggered by the pathogens. 
Maturing DCs migrate from the site of infection to the draining lymph nodes where they 
come in contact with naïve T cells. They present the endocytosed and degraded antigens 
(peptides) in the context of MHC molecules to T cells in order to induce antigen specific 
acquired immunity.  
In vitro studies have shown that C. trachomatis and C. psittaci are taken effectively into 
mouse dendritic cells through micropinocytosis and the Chlamydia-containing endosomes 
fuse with lysosomes. The bacteria are degraded for subsequent presentation on MHC class 
II molecules (Ojcius et al., 1998; Prebeck et al., 2001). C. pneumoniae has been shown to 
stimulate bone-marrow derived murine dendritic cells (BMDDC) to express MHC class II 
and costimulatory molecules such as CD40, CD80, and CD86 and also to activate NF-κB 
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signal transduction pathway resulting in dendritic cell maturation. BMDDC stimulation by 
C. pneumoniae was only partially dependent on TLR4, which determines responses to gram 
negative bacteria through binding to LPS (Prebeck et al., 2001). Instead, TLR2 was shown 
to be involved in dendritic cell stimulation in C. pneumoniae infection possibly through 
recognition of C. pneumoniae Hsp60 molecule secreted by the C. pneumoniae infected cells 
(Costa et al., 2002).  
 
Acquired immunity 
Acquired immunity is a result of naïve T helper cell (Th; CD4+ T cells) stimulation by 
antigen presenting cells (APC) that leads to immediate effector functions, characterized by 
humoral response and cell mediated immunity (CMI), as well as to immunological memory.  
Cell-mediated immunity 
Under stimulation of certain type of dendritic cells and influence of certain type of 
cytokine milieu, naïve T helper cells differentiate into cells either secreting Th1 type 
cytokines (e.g. IFN-γ, TNF-α) or Th2 type cytokines (e.g. IL-4, IL-5, IL-6, IL-13)(Gumy et 
al., 2004). Th1 type of response is typical for protective immunity against many intracellular 
pathogens. The response results in a stimulation of cytotoxic CD8+ T cells (or e.g. 
macrophages) that are able to destroy cells infected with intracellularly hiding microbes. 
CD8+ T cells recognize antigen derived peptides in the context of MHC class I molecules, 
that are expressed on the surface of any kind of cell type. Th2 type immune response 
integrates with humoral immunity: B cells are stimulated to produce antibodies that 
primarily act through neutralization of extracellular microbes (Guermonprez et al., 2002). A 
strict division of immune responses to either Th1 type or Th2 type immunity is 
oversimplification. Besides activating macrophages and CD8+ T cells, Th1 type immunity 
induces in mice production of IgG2a antibodies that act through opsonizing and 
complement-fixation. Th2 type immunity not only induces B cell antibody production but 
inhibits activation of macrophages through the action of IL-10 (Debattista et al., 2003). 
Also, the infection may induce a mixed Th1/Th2 type response rather than a strictly 
polarized response to either direction. 
The Th1 versus Th2 type immune responses play a role in chlamydial immunobiology. It 
has been suggested that Th1 type response characterized by IFN-γ production is associated 
with the clearance of chlamydia, while Th2 type immune pattern with IL-4 and IL-10 
contributions fails to clear the infection and leads to persistence and promotes pathology 
(Brunham, 1999; Debattista et al., 2003). For example, the development of persistent ocular 
C. trachomatis infection in humans resulting in trachoma has been associated with increased 
stimulation of Th2 cytokines by the peripheral blood mononuclear cells isolated from the 
trachoma patients (Holland et al., 1996). 
After phagocytosing chlamydia, mouse dendritic cells secrete IL-12, which promotes the 
Th1 type response (Ward, 1999). IFN-γ neutralization exacerbates the C. pneumoniae 
reinfection in mice which emphasizes the effector role for IFN-γ in protection (Penttila et 
al., 1999; Vuola et al., 2000). Protection against C. pneumoniae rechallenge is also 
dependent on CD8+ T cells rather than CD4+ T cells, and this could suggest the role of 
CD8+ T cells on producing IFN-γ (Penttila et al., 1999). In another chlamydial pulmonary 
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model, C. trachomatis MoPn model, the mice deficient in CD4+ T-cell function (knock-out 
MHC class II -/- mice) that lacked antibodies but did produce IFN-γ (probably by CD8+ T 
cells and NK cells) were very susceptible to reinfection of MoPn, that has been suggested to 
show a critical role of CD+ T cells in resistance to reinfection (Williams et al., 1997). 
However, the result may also emphasize the critical role of CD4+ T cells during priming, 
which in these knock-out MHC class II mice has not either been complete and therefore 
probably has also affected on development of functional CD8+ T cells (Sun and Bevan, 
2003). 
There are several mechanisms for IFN-γ control over C. pneumoniae infection. In vitro 
studies have shown that IFN-γ induces inducible nitric oxide synthase (iNOS) activity in 
murine macrophages or in epithelial cells. iNOS gene knockout mice have increased 
susceptibility to C. pneumoniae infection (Rottenberg et al., 2002). Mice show increased 
bacterial load, dissemination and more severe pathology in the infected tissue. However, 
IFN-γR-/- mice are even more sensitive to C. pneumoniae infection that suggests also other 
effector pathways for IFN-γ than iNOS. But on the other hand, a possible mechanism for 
IFN-γ inducible C. pneumoniae growth restriction in human cells could be an induction of 
indoleamine-2,3-dioxygenase (IDO) expression. IDO catabolizes intracellular tryptophan in 
the host cytoplasma and limits thereby its availability to C. pneumoniae (Beatty et al., 
1994). C. pneumoniae lacks the genes for tryptophan biosynthesis of its own and is 
therefore strictly dependent on hosts storage of tryptophan. Also, other IFN-γ inducible 
effects could be e.g. iron deprivation. But taken together, although in vitro and in vivo 
studies have revealed different mechanisms for IFN-γ effect, their relative roles are still 
unknown (Rottenberg et al., 2002). In cell culture, IFN-γ treatment eradicates the bacteria 
from the cells, but when the level of IFN-γ is low persistent infection develop (Beatty et al., 
1994) (Fig. 3). In vivo, low levels of IFN-γ may be a result of too weak Th1 type immune 
response or a dominant Th2 type immune response. The important question remains, how to 
induce optimal IFN-γ response that would rather confer bactericidal effect with the 
clearance of infection than bacteriostatic effect with the establishment of persistent 
infection.  
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Figure 3. The effect of IFN-γ on Chlamydia developmental cycle (modified from (Rottenberg et al., 
2002)). 
 
 
However, as a reminder of complexity of the immunity, Th1 response may not only be 
beneficial to the host by promoting chlamydial clearance. In fact, too vigorous Th1 response 
may also result in inflammatory damage through the action of cytotoxic T cells and lead to 
tissue damage (Debattista et al., 2003). Therefore, induction of anti-inflammatory cytokine, 
IL-10, during the chlamydia infection may also be beneficial or even essential in order to 
avoid pathological tissue damage.  
Humoral immunity 
The role of antibodies in the protection against chlamydial infections is probably less 
significant than the role of CMI. In pulmonary C. pneumoniae infection model, the adoptive 
transfer of convalescent serum to nude or BALB/c mice did not confer protection against 
the subsequent challenge (Penttila et al., 1999), and in NIH/S mice passively transferred 
antibodies partially reduced pulmonary bacterial counts but not inflammatory reaction 
(Kaukoranta-Tolvanen et al., 1995). Serum antibodies have not been shown to be critical, 
but play a partial protective role in C. trachomatis MoPn pulmonary model. B-cell deficient 
mice (ko. Igh-/- or µMT) which produce no antibodies and are devoid of mature B cells (no 
antigen presentation) were susceptible to reinfection. Especially, the deficiency had an 
effect on T cells causing impaired responses to chlamydial antigens (Williams et al., 1997; 
Yang and Brunham, 1998). Interestingly, Moore et al. (Moore et al., 2002; Moore et al., 
2003) have suggested that in the genital C. trachomatis infection model specific antibodies 
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play an important role in opsonizing chlamydial particles and thereby augmenting the FcR-
mediated effector functions of dendritic cells to enhance Th1 response.  
In contrast to the minor role of serum antibodies, the activity of local antibodies, 
especially mucosal IgA antibodies may have an important role. To date, there is very little 
data on the significance of mucosal IgA response for the protection against C. pneumoniae 
infection either in humans or animals, but in C. trachomatis infection, the prevalence of IgA 
antibodies in mucosa is related to faster clearance as well as reduced shedding of bacteria 
both in humans and various animal models (Brunham, 1999; Lu et al., 2002; Rank, 1999).   
An ideal vaccine candidate should induce long-lasting acquired immunity to protect 
against the microbial infection. The few studies on protective immunity against C. 
pneumoniae suggest that a vaccine capable of inducing a Th1 type immune response, 
characterized by IFN-γ release as an effector mechanism, may clear the subsequent infection 
efficiently. CD8+ T cells are possibly needed for the secretion of this cytokine. 
1.4. Vaccines inducing cellular immunity 
1.4.1. General requirements 
 
Most of the current vaccines are killed or inactivated microorganisms, their subunits, 
recombinant proteins or their subunits; altogether, they are so called exogenous antigens. 
These antigens are taken up by antigen presenting cells (APCs), by phagocytosis, and 
presented mainly in the context of MHC class II molecules. Peptides, in the context of MHC 
II molecules, are recognized by CD4+ T cells, which in turn depending on surrounding 
cytokine milieu differentiate into Th1 or Th2 cells. Usually, with exogenous antigens, Th2 
type immune response is induced and generates effective antibody response (Gurunathan et 
al., 2000). 
However, CD8+ T cell activation requires peptide recognition in the context of the MHC 
class I molecules. The antigens that are associated with the MHC I molecules are generally 
synthesized inside the cell (e.g. live viruses) (Gurunathan et al., 2000). However, the use of 
live microbes (even attenuated ones) as vaccines is undesirable. Attenuation of the microbes 
may be incomplete, or the attenuated microbe may revert back to a pathogenic one. This 
possibility for reversion in some vaccines may be a safety concern for the vaccinated 
individuals and the widespread use of this type of vaccines should be avoided.  
1.4.2. DNA vaccines 
 
DNA vaccines resemble live attenuated vaccines. Direct in vitro or in vivo transfer of 
recombinant DNA results in the expression of the recombinant protein inside the cell. 
Therefore, the antigen can be processed in the cytoplasm and presented in the context of 
MHC class I molecules. This leads to activation of CD8+ T cells. Compared to the live 
attenuated vaccines, the safety concerns are bearable.  
Although, DNA vaccines are thought to exquisitely activate CD8+ T cells, both humoral 
and cellular immune responses are induced after the DNA immunization (Gurunathan et al., 
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2000). Presumably, at the site of the DNA immunization, various cell types become 
transfected with the plasmid, and the expression of the desired gene can take place also in 
other cells than in the professional antigen presenting cells (APCs). However, these other 
cells are devoid of costimulatory molecules and are not able to stimulate naïve T cells. 
Therefore, the direct transfection of professional APCs at the site of immunization is the 
critical event for successful priming of immune cells. However, the professional APCs, such 
as dendritic cells, may get their antigens also exogenously and still be capable of presenting 
these antigens on their surface in the context of MHC I molecules and prime CD8+ T cells. 
The phenomenon is termed as cross-presentation (or cross-priming) (Guermonprez et al., 
2002). Although, both APC stimulation mechanisms appear to be involved, the cross-
priming has suggested to be the main mechanism in the type of DNA immunizations (Boyle 
et al., 1997; Corr et al., 1999). 
The fact that the DNA vaccines presumably induce Th1 type immune responses relies 
mainly on the adjuvant effect of certain unmethylated purine-purine-CG-pyrimidine-
pyrimidine (CpG) motifs being present in DNA plasmids. DNA plasmids contain 
sequences of bacterial DNA (e.g. antibiotic resistance genes), and bacterial DNA include 
frequent unmethylated CpG motifs (Krieg, 2002). The host dendritic cells recognize these 
motifs as pathogenic compounds through their Toll-like receptor (TLR) 9 (Guermonprez et 
al., 2002). In many infection models, stimulatory CpG motifs enhance especially IFN-γ and 
IL-12 expressions, and, at the same time, diminish IL-4 production, suggesting their ability 
to specifically induce Th1 type immune response (Gurunathan et al., 2000).  
Humoral response induced by DNA vaccines is dose-dependent and enhanced after 
multiple injections (Gurunathan et al., 2000). The antibody titers and avidity are usually 
lower in mice vaccinated with DNA than in those vaccinated with protein or whole 
microbes. All antibody subtypes are produced, but as the Th1 type immune responses are 
more common after DNA vaccination, the observed humoral response is often IgG2a 
biased. However, if the expressed protein coded by DNA vaccine is secreted, the dominant 
IgG subtype is usually IgG1 (Boyle et al., 1997; Gurunathan et al., 2000). The viral antigens 
expressed after DNA immunizations can attain their native conformation and result in 
induction of antibodies that can neutralize pathogen. However, if the expressed antigen is a 
bacterial protein, the expression inside the eukaryotic cell might be suboptimal, and the 
native conformation of the antigen may not be attained. This may hinder the emergence of 
specific neutralizing antibodies. However, there is no consensus on the molecular 
requirements of the antigen (whether it should be secreted, cytoplasmic or membrane-
bound) to attain optimal processing for adequate presentation and desired immune 
responses; on the contrary, this varies a great deal depending on the antigen and the 
infection model. 
DNA vaccines have induced protective immune responses in rodent models against 
many diseases caused by intracellular pathogens, such as influenza (Ulmer et al., 1993) 
(Robinson et al., 1993), malaria (Sedegah et al., 1994) and mycobacterium (Lowrie et al., 
1997), but the protection has usually been only partial. This is thought to be related to the 
inefficient in vivo gene delivery into the host, and also to the relatively poor antigen 
expression in the transfected cells (Bergmann-Leitner and Leitner, 2004). Indeed, at present, 
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one of the major areas of research is to improve DNA plasmids, in order to increase the 
amount of antigen expressed by the vector, or to enhance the immunogenicity of the vector 
itself, e.g., new stronger promoters are incorporated in the plasmids, and more 
immunostimulatory CpG motifs are inserted to the plasmid backbone.   
DNA vaccines have the potential to facilitate the screening and evaluation process of 
vaccine candidate antigens dramatically (Gurunathan et al., 2000; Murdin et al., 2000). 
Instead of preparing recombinant proteins, many open reading frames can be cloned into 
eukaryotic expression vectors and the plasmids for immunization of experimental animals 
can be produced efficiently and rapidly. Even plasmid pools or expression libraries can be 
tested for protective efficacy. Consequently, this makes it possible to quickly respond to the 
urgent need for designing new vaccines (Yang et al., 2004). Also, if DNA vaccine were 
accepted for clinical use, the manufacturing of the vaccines would be relatively cost-
effective with no concern about storage problems. However, there are some concerns about 
the long-term effects of DNA immunization. In vitro transfected DNA plasmids can 
integrate into the host cell genome. If this happened in vivo, it could lead to a greater risk 
for cancer formation by inadvertent activation of oncogenes. However, to date any clear 
evidence of in vivo integration or harmful side effects of DNA vaccines is missing 
(Gurunathan et al., 2000; Nichols et al., 1995).  
1.4.3. Viral vectors 
 
Use of viral vectors is another possibility to deliver the antigen of interest inside the host 
cell. For this purpose, several viral vector expression systems exist. Systems can be based 
on DNA or RNA viruses, on replication competent or incompetent viruses, on genome 
integration or episomal replication, and on different viruses with different cell tropisms 
(Bonnet et al., 2000; Lundstrom, 2003). At present, the most used viral vector systems in 
immunization studies are adeno-associated viruses (AAV), adenoviruses, alphaviruses, 
herpes simplex viruses (HSV), poxviruses, and retroviruses (Lundstrom, 2003).  
Virus vectors have some advantages over the DNA vaccines. They can efficiently infect 
host cells, and they mimic natural infection, thereby, inducing a potent immune response 
(Bonnet et al., 2000). Viral capsid proteins may enhance the inflammation itself by inducing 
proinflammatory cytokine expression of infected cells, and thereby, attracting more antigen 
presenting cells to the site of immunization (Seder and Hill, 2000). In addition, a cytopathic 
effect of some virus vectors may also result in an efficient antigen presentation and priming 
of the immune responses, since APCs efficiently take up apoptotic bodies originating from 
virus-infected cells (Bonnet et al., 2000).  
Attention must be paid on safety aspects when virus-based vectors are applied for human 
immunizations. The use of non-replicative viruses as vaccines is more desirable. Indeed, 
many vectors have been manipulated by deleting the essential genes for generating new 
viral particles in the vaccinated individual. Also, as some viruses have an ability to integrate 
into the host genome (e.g. retroviruses), a risk for causing unwanted insertional mutagenesis 
is real when these types of constructs are used. The aforementioned advantage that the viral 
proteins may enhance inflammation may also be a disadvantage. Pre-existing immune 
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responses may hamper the delivery of some ubiquitous viruses used as vaccines (e.g. 
adenoviruses) and preclude multiple immunizations, which is usually a prerequisite to a 
potent immune response.(Bonnet et al., 2000; Lundstrom, 2003). 
The lack of pre-existing human immunity against alphaviruses makes them suitable 
vaccine candidates for clinical use (Schnell, 2001). Alphaviruses are single-stranded RNA 
viruses. They infect a broad range of cell types. Therefore, they are effective in delivering 
any RNA of interest into eukaryotic cells. After infection, viruses attain the cytoplasmic 
compartment of the cell, and the expression levels of the encoded proteins are high. In vitro 
transfection of cells with alphavirus replicon (e.g. Semliki Forest virus), where viral 
structural proteins have been replaced with the gene of interest, together with helper 
replicon(s) coding only the viral structural proteins, generates the recombinant virus 
particles inside the transfected cells. As only the recombinant replicon is packed into these 
progeny viral particles, vaccination with these particles results in replication and subsequent 
translation of the gene of interest only, but the virus itself is not further produced (Smerdou 
and Liljeström, 1999) (Fig.4). 
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Figure 4. The in vitro packing of recombinant SFV particles (modified from (Schlesinger, 1999)). 
The cells are transfected with the replicon RNA where viral structural protein genes have been 
replaced with the gene of interest (heterologous protein gene) and with defective helper RNAs, 
which contain viral structural genes but do not have non-structural protein genes required for 
replication, transcription and RNA packing into progeny virions.  
 
 
The efficacy of alphavirus vaccines against both cancer and infectious diseases is well 
documented (Lundström, 2001; Tubulekas et al., 1997). Vaccines based on the recombinant 
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suicidal self-replicating alphavirus, Semliki Forest virus (SFV) have successfully been used 
to protect mice against influenza, flavivirus and respiratory syncytial virus (RSV) infection 
(Berglund et al., 1999; Chen et al., 2002; Fleeton et al., 1999; Zhou et al., 1995). 
Furthermore, immunization with this viral vector induces a strong humoral and cellular 
immune response with apparent long memory (Zhou et al., 1995). Self-replicating SFV 
RNA induces the host cell death by apoptosis, which has been suggested to enhance cross 
priming of dendritic cells (Albert et al., 1998; Glasgow et al., 1998).  
1.4.4. Heterologous prime-boost regimens 
 
The DNA vaccines and recombinant viral vector vaccines have both been successful in 
inducing potent cell-mediated immunity (CMI). However, in some infection models these 
vaccine vectors have induced insufficient immunity to afford protection against the 
challenge of a pathogen (Ramshaw and Ramsay, 2000). The insufficient immune responses 
have been enhanced by combining the DNA immunization with another type of vaccination 
(e.g. viral vector) in prime-boost strategy. 
First demonstration of heightened immunogenicity came up with the studies in HIV and 
malaria models (Ramsay et al., 1997; Schneider et al., 1998), where mice were parenterally 
first primed with DNA and boosted later with recombinant viral vector encoding the same 
antigens of the pathogen. This immunization strategy resulted in a typical Th1 type immune 
response in mice that was characterized by IFN-γ secreting CD8+ T cells responsible for the 
protection, and by induction of specific antibodies with predominantly IgG2a subtype 
(Ramshaw and Ramsay, 2000). Interestingly, reversing the order of immunization or 
changing the viral vector strain did not afford protection.  
Why priming with DNA prior to viral vector boosting is beneficial to attain enhanced 
immune responses and offers in most cases better protection is not known. Some features 
have been suggested to contribute to the observed efficacy of this type of immunization 
(Ramshaw and Ramsay, 2000). The CpG motifs in DNA vectors strongly stimulate IL-12 
production and would therefore favor CMI responses. Also, a relatively low-level, but 
persistent expression of antigen by DNA vectors may generate high affinity T cells, which 
then are expanding after boosting with viral vectors, that in turn express high levels of 
encoded protein. However, all these explanations of the possible mechanisms are still 
speculative and may not be generalized to all prime-boost regimens especially in every 
infection model. In a vaccinia vector immunization model, the use of mucosal route for 
immunization changed the general rule for optimal order in vaccine regimen. Surprisingly, 
priming with vaccinia viral vector and boosting with DNA gave the best protection (Eo et 
al., 2001). Nevertheless, whatever the precise mechanism is, DNA priming and viral vector 
boosting with modified vaccinia virus Ankara (MVA), has repetitively proven to be a 
superior vaccination strategy in many infectious models, and in several different animal 
models, and these good preliminary results have now been confirmed also in human 
vaccination programs (McConkey et al., 2003). 
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1.5. Antigenic proteins of C. pneumoniae  possible vaccine 
candidates 
 
Recently, the genomes of C. trachomatis and C. pneumoniae have been sequenced 
(Kalman et al., 1999; Stephens et al., 1998), and the new data available has given an 
opportunity to screen great numbers of new vaccine candidates. In an attempt to design a 
vaccine against infectious agent, a feasible starting point is to look at the microbial surface-
exposed proteins. This is especially useful when the immune protection against the 
infectious disease specifically involves humoral, neutralizing antibodies. Indeed, 
neutralizing antibodies frequently correlate with protection against many infectious 
microbes (Zinkernagel, 2002). In the case of cellular immunity, the major determinant for a 
proper immunogen may not be surface-exposure of the antigen on microbe itself: it has to be 
efficiently presented on the surface of infected host cell in the association with MHC I-
molecules and the microbe should not prevent antigen presentation. For such presentation, 
the antigen must have been drifted inside the host cytosol where it can be properly 
processed to peptides, which then are attached to newly synthesized MHC I-molecules.  
How does this fit together with the chlamydial developmental cycle? The bacteria live 
most of their intracellular, metabolically active phase of the developmental cycle strictly 
inside the inclusion. Chlamydia is able to make its proteins itself, and only if chlamydial 
proteins appeared into the host cytosol, they would have been transported there from the 
inside of the inclusion. The amount of such proteins can be rather low in comparison with 
the viral proteins that are expressed by the host. There are several C. pneumoniae protein 
families that probably are transported to the hosts cytosol, or at least they are a part of the 
endosomal membrane. These protein families are inclusion membrane proteins (Incs) and 
type III secretion apparatus proteins as well as their substrates. There are many host cell 
factors (proteolytic, ubiquitination, suppressive peptides, etc.) that influence the antigen 
processing pathway and that determine which peptides finally enter onto the surface in the 
context of MHC molecules. 
Chlamydia antigens may also become available for antigenic presentation in very early 
phase of infection, if chlamydia inside the endosome is not able to inhibit phagolysosomal 
fusion of the vesicle. Also, during the late phases of developmental cycle when inclusion 
membrane ruptures, released chlamydia particles are vulnerable for hosts proteolytic 
action. In these cases, any protein of chlamydia particles (both from EB and RB) could be a 
target for degradation in the cytosol and its epitopes could be processed for presentation. 
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1.5.1. Outer membrane proteins  
 
 
 
 
 
Figure 5. Schematic structure of chlamydial outer membrane protein (Hatch, 1999) (courtesy of 
ASM Press). 
 
 
 MOMP 
Sera of infected individuals recognize several proteins of C. pneumoniae (Campbell et 
al., 1990b; Iijima et al., 1994; Jantos et al., 1997). One of the best-characterized antigens 
among the Chlamydia species is the major outer membrane protein (MOMP, ompA). This 
43-kDa protein apparently assembles as a trimer within the outer membrane and functions 
as a porin channel when chlamydiae are in a metabolically active form, in reticulate bodies 
(RB) (Bavoil et al., 1984; Everett and Hatch, 1995; Jones et al., 2000; Wyllie et al., 1998) 
(Fig. 5). The structural conformation of MOMP during the extracellular phase of the 
developmental cycle is unknown. The MOMP (like other chlamydial outer membrane 
proteins) is heavily cross-linked by disulfide bridges conferring thus integrity for the 
bacteria to resist osmotic pressure. The protein has four variable domains (VD1-4) that are 
located at the outer loops of the porin structure and five constant domains on beta-strands 
and the periplasmic loops (Rodriguez-Maranon et al., 2002). MOMP is an immunodominant 
antigen in C. trachomatis inducing production of neutralizing antibodies during infection 
(Su and Caldwell, 1991). Also, CD4+ T cell epitopes have been identified in the MOMP of 
C. trachomatis (Allen and Stephens, 1993; Stagg et al., 1993; Su et al., 1990). Despite the 
remarkable sequence similarity between the MOMPs of chlamydial species, C. pneumoniae 
MOMP has not been considered to be immunodominant or at least it is antigenically 
complex (Campbell et al., 1990a). However, few monoclonal antibodies have been shown to 
recognize species-specific antigen of C. pneumoniae and also been able to neutralize 
infection in vitro (Puolakkainen et al., 1995; Wolf et al., 2001). One such antigen has been 
further precipitated from C. pneumoniae infected cells, and subsequently, characterized by 
sequencing as MOMP (Wolf et al., 2001). The antigenic epitope of MOMP was strictly 
conformational and may explain the incapability of the earlier Western blot experiments in 
showing any recognition between patient sera and denatured form of MOMP. The protein is 
evidently localized on the surface of C. pneumoniae, but it may also be masked by other 
chlamydial outer membrane proteins, for example, possible surface layer proteins (Knudsen 
et al., 1999). Generation of protective neutralizing antibodies against this epitope may 
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definitely be an approach in developing vaccine against C. pneumoniae infection, but 
unlikely for sterilizing immunity.  
 
 Omp2 
Another outer membrane protein, a cysteine-rich protein, Omp2 (60 kDa, omcB), has 
been identified as a major target for immune recognition in both C. trachomatis and C. 
pneumoniae infections (Essig et al., 1999; Mygind et al., 1998b; Wagar et al., 1990). This 
protein is heavily cross-linked by disulfide bonds in EB forms of Chlamydia, and is 
probably located in the periplasmic layer in a close association with the inner surface of 
outer membrane (Everett and Hatch, 1995; Mygind et al., 1998a) reviewed by (Hatch, 1996) 
(Fig. 5). In addition, it is disulfide cross-linked to the small cysteine-rich lipoprotein (12 
kDa, omcA), and this complex of the proteins has been proposed to be the functional 
equivalent of the absent peptidoglycan in Chlamydiae (reviewed by (Hatch, 1996)). 
Although, the immune response against this protein is strong, it is also genus specific 
(Mygind et al., 1998b), and utilization of this antigen as vaccine candidate would probably 
affect all chlamydial infections. This might not be an unwanted result, if the desired 
protective immune correlates are proven to be similar in infections due to all chlamydial 
species. The short species-specific sequence in amino-terminal fragment of Omp2 has 
shown limited immunogenicity, at least when it is in a denatured form. However, 
conformational, non-linear epitopes of the particular fragment have not been studied 
(Mygind et al., 1998b).  
 
 Pmps 
The analysis of the genome sequences of Chlamydiae, for tracking potential new outer 
membrane proteins, revealed a new family of polymorphic membrane proteins (Pmps) 
(Longbottom et al., 1998; Stephens and Lammel, 2001). In fact, a cysteine-rich protein with 
a molecular mass of 98 kDa was found in the C. pneumoniae outer membrane complex 
earlier (Melgosa et al., 1993) and it has also shown to be immunoreactive in C. pneumoniae 
infections (Campbell et al., 1990b). Knudsen et al. first identified the C. pneumoniae genes 
encoding proteins of this size, omp4 and omp5 (Knudsen et al., 1999). The C. pneumoniae 
genome encodes for 21 polymorphic membrane proteins, which are all transcribed but only 
11 of the 21 are translated, and only a few of those are stably translated or present in the 
membrane (Grimwood et al., 2001). Furthermore, it has been demonstrated that the 
expression of Pmps varies within and between different C. pneumoniae isolates, as 
evidenced by either diversity or frameshifts in sequence that results in different molecular 
weights of the proteins and expression levels (Grimwood et al., 2001; Knudsen et al., 1999; 
Mygind et al., 1998a). The precise function of these proteins is still unknown. Suggested by 
the predicted structures, motifs and the cleavage sites of the protein, Pmps resembles in 
many way auto-transporter proteins (Henderson and Lam, 2001; Vandahl et al., 2002). As 
they are polymorphic proteins at the bacterial surface, they are suggested to represent 
chlamydial S-layer proteins and therefore, may have an essential role for the virulence and 
pathogenesis of C. pneumoniae (Fig. 5)(Grimwood et al., 2001; Knudsen et al., 1999; 
Stephens and Lammel, 2001). 
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1.5.2. Inclusion membrane proteins (Incs) 
 
Chlamydiae persist during their intracellular developmental cycle within an inclusion. 
They modify the nascent inclusion to resist lysosomal fusion and instead interact with 
sphingomyelin and cholesterol trafficking exocytic pathway (Fields and Hackstadt, 2002). 
The first inclusion membrane associated proteins were found by comparing the serological 
response of C. psittaci infected animals against purified Chlamydia EBs, chlamydia infected 
cells, and uninfected cells (Rockey and Rosquist, 1994). The sera identified some antigens 
only in the preparations made from the infected cells, and immunofluorescence staining 
showed that the antigens were localized in the inclusion membrane. When the sera were 
used to screen bacteriophage expression libraries, C. psittaci IncA, IncB and IncC were 
found (Rockey et al., 2002). Homologs to IncA, B and C proteins within other Chlamydia 
species were found by screening the genomic sequences (or predicted protein sequences) of 
C. pneumoniae and C. trachomatis for proteins that possessed the characteristic 
hydrophobic secondary structure of Incs (Rockey et al., 2002). Screening of C. trachomatis 
genome has revealed up to 40 proteins sharing the characteristic feature (Fields and 
Hackstadt, 2002). These studies have shown that 29 of the putative Inc proteins are 
expressed early in the developmental cycle (at 2h post infection), earlier than, for example, 
chlamydial structural genes that are expressed in mid-cycle. This may suggest that the 
manipulation of the inclusion membrane is a prerequisite for successful chlamydial 
multiplication. Although genes encoding for Inc proteins are found in C. pneumoniae 
genome, only IncA has been demonstrated in the inclusion membrane. IncB and IncC of C. 
pneumoniae are evenly distributed inside the inclusion (Lugert et al., 2003). The function of 
all chlamydial Inc proteins is still unknown, but according to their location at the interface 
of the inclusion and the host cytoplasm, they probably are main candidates of being 
involved in the interaction between the host and the pathogen (Fields and Hackstadt, 2002). 
1.5.3. Type III secretion system (TTSS) 
 
Already in late 70s and early 80s, Gregory et al. and Matsumoto observed hemispheric 
surface localized projections on the C. psittaci and C. trachomatis EB in their scanning 
electron microscopy pictures. These projections have then later been suggested to 
correspond to the type III secretion system (TTSS) (Fields and Hackstadt, 2002). Via this 
secretion system, gram-negative bacteria can modulate eukaryotic cells by injecting 
bacterial proteins across the two bacterial membranes and the eukaryotic cell membrane 
(Cornelis and Van Gijsegem, 2000). The genome of C. trachomatis and C. pneumoniae 
contains genes for the apparatus, and the purified spikes of EB have similar structures to 
purified components of Salmonella typhimurium TTSS (Fields and Hackstadt, 2002). The 
function of the whole chlamydial TTSS apparatus proteins has not been elucidated yet, but 
studies with C. trachomatis L2 strain have shown that type III components are present on 
EB throughout the early infectious process before de novo protein synthesis of the 
apparatus, which proceeds during the mid-cycle of the infectious cycle (Fields and 
Hackstadt, 2000). Subtil et al. (Subtil et al., 2001) have shown that C. pneumoniae Inc 
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proteins can be secreted by a heterologous type III machinery of Shigella. The authors 
speculate that Chlamydia could apply the TTSS in inserting proteins into the inclusion 
membrane. Indeed, the two observations  a very early expression of Inc-proteins and a 
functional TTSS apparatus on the infectious form of EB - suggest that TTSS apparatus may 
already function in the early phase of infectious cycle, at the time, when inclusion 
membrane associated proteins should be secreted out of the chlamydia (Fields et al., 2003). 
Another protein, CopN (or LcrE), which belongs to the apparatus itself as a putative lid, 
has also shown to be secreted by the secretion system to the inclusion membrane, but with 
an unknown function (Fields and Hackstadt, 2000; Lugert et al., 2003). The fact that type III 
secretion apparatus in gram-negative bacteria is usually related to their pathogenesis makes 
them attractive candidates for vaccine design (Cornelis and Van Gijsegem, 2000).  
1.5.4. Heat shock proteins (Hsps) 
 
Heat shock proteins are ubiquitous proteins that function as chaperons ensuring 
expressed new proteins to become functionally correct molecules. This chaperone protein 
family consists of proteins ranging from 15 to 110 kDa proteins. They are expressed in 
response to various stress such as heat, chemicals, inflammation etc. (Debattista et al., 
2003). As versatile proteins they also contribute to other cellular housekeeping functions 
during the synthesis, aggregation and packaging of newly synthesized proteins (Debattista et 
al., 2003). Hsps are phylogenetically very conserved proteins among all living organisms 
from bacteria to humans.  
Despite of similarities of Hsps among living organisms (or because of that), bacterial 
Hsps are also involved in disease pathogenesis (Zugel and Kaufmann, 1999). The exact 
mechanism how Hsps are involved in adverse effects of immune response is not known. In 
C. trachomatis infections, high chlamydial Hsp60 (GroEL) antibody titers of humans with 
pelvic inflammatory disease (PID) correlate with more severe inflammatory manifestations 
of the disease (Debattista et al., 2003; Eckert et al., 1997). Also, C. pneumoniae Hsp60 and 
Hsp10 (GroES) specific antibodies were more prevalent among the asthmatic adults than 
their healthy controls (Betsou et al., 2003; Huittinen et al., 2001) and Hsp60 antibody levels 
correlated with the presence of C. pneumoniae antigen in atheromas (Fong et al., 2002b). 
Hsps are cytoplasmic, abundantly expressed proteins that can become available antigens to 
the host antigen presenting cells, for example when the infected cells disrupt when they 
undergo necrosis. IFN-γ induces the expression of chlamydial heat shock proteins. 
Therefore, the persistent state of infection could lead to a continuous presence of Hsp 
antigens and a stimulation of immune response (Debattista et al., 2003).  
The possible use of abundant microbial Hsps as vaccines is a two-edged sword. In some 
infection models, e.g. Mycobacterium tuberculosis and Helicobacter pylori infection 
models, Hsp60 or Hsp70 immunization with proteins or DNA have conferred protection 
against the infection, as well as an adaptive transfer of Hsp specific T cells has mediated at 
least a partial protection (Zugel and Kaufmann, 1999). However, the molecular mimicry of 
Hsps could be a reason for self-reactive T cells falsely activated by pathogenic homologs of 
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Hsp determinants and react against self-antigens, thereby evoking detrimental 
immunopathology (Zugel and Kaufmann, 1999).  
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2. Aims of the study 
 
The specific aims of the present project were: 
 
i. to screen selected C. pneumoniae open-reading frames for their ability 
to elicit protective responses in mouse pulmonary infection model 
ii. to evaluate immunogenicity and efficacy of two different vaccination 
regimens (DNA vaccination and DNA prime  SFV boost vaccination) 
in mice 
iii. to develop assays for detecting mouse antibody responses after 
immunizations and C. pneumoniae infections 
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3. Materials and methods 
 
The materials and methods used in this study are described in detail in the indicated 
articles. 
 
Bacterial strains and cell lines used in this project 
 
Strain or 
cell line Description Article Source or reference 
Bacterial 
strain: 
   
K6 C. pneumoniae isolate Kajaani 6 
(K6) 
I - IV Prof. Saikku, University 
of Oulu (Ekman et al., 
1993) 
JM109 E. coli II , III  
DH5α E. coli II, III  
IH6140 B. subtilis 1A289, NNG 
mutagenized, reduction of total 
protease 
I (Sibakov, 1986) 
WB600 B. subtilis WB600 (trpC2 ∆nprE 
∆aprE ∆eprE ∆bpf ∆mpr ∆nprB) 
I (Wu et al., 1991) 
168 B. subtilis trpC2 I (Anagnostopoulos and 
Spizizen, 1961) 
IH7339 B. subtilis 168 carrying pKTH3415 I I 
IH7115 B. subtilis WB600 carrying 
pKTH3361 
I I 
IH7279 B. subtilis IH6140 carrying 
pKTH3391 
I I 
IH7342 B. subtilis WB600 carrying 
pKTH3418 
I I 
Cell lines: 
 
   
HL Human lung epithelial cell line I - IV (Ekman et al., 1993) 
P815 Mouse mastocytoma cell line II ATCC number 
TIB-64 
COS-7 African green monkey kidney cell 
line 
II, III ATCC number CRL-
1651 
BHK-21 Baby hamster kidney cell line III ATCC number CCL-10 
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Plasmids and recombinant constructs used in this project.  
 
Plasmid Description Source or reference 
pKTH39 cytoplasmic expression vector, amyQ promoter, 
ribosome binding site and 7 aminoterminal codons of 
amyQ signal peptide in front of cloning site EcoRI 
(Palva et al., 
1982) 
pKTH1784 like pKTH39, cloning site HindIII (Saris et al., 
1990) 
pKTH3415 like pKTH39, cloning site KpnI 
primers: 
F: 5 aaccggatccatcgattgtttgagaaaag 3 
R: 5 cggaattcggtaccccgctttcgtttttgaa 3 
I 
pKTH3361 pKTH39 having C. pneumoniae Hsp60-His6 encoding 
insert at EcoRI 
primers: 
F: 5 ggaattcgatggcagcgaaaaat 3 
R: 5 ggaattcttagtgatggtgatggtgatgtcctccgtagtccattcctg 
3  
I 
pKTH3391 pKTH1784 having C. pneumoniae Omp2-His6 
encoding insert at HindIII 
primers: 
F: 5 gccgaaagcttaagcgggggtatagag 3 
R: 5 gccgtaagctttttagtgatggtgatggtgatgtcctccatac 
acgtgggtatt 3 
I 
pKTH3418 pKTH3415 having C. pneumoniae MOMP-His6 
encoding insert at KpnI 
primers: 
F: 5 cgggtaccttgcctgtagggaac 3 
R: 5 cgggtaccttagtgatggtgatggtgatgtcctccgaatctga 
actgacc 3 
I 
pcDNA3.1  Eukaryotic expression vector Invitrogen® 
pmomp pcDNA3.1 having C. pneumoniae MOMP encoding 
insert at BglII 
primers: 
F: 5 gtaagatctccaccatgaaaaaactcttaaagtcg 3 
R: 5 catagatctttagaatctgaactgaccagatac 3 
II, III 
pomp2 pcDNA3.1 having C. pneumoniae Omp2 encoding 
insert at BamHI 
primers: 
F: 5 ggcgacggatccaccatgtccaaactcatcagacga 3 
R: 5 gacggatccttaatacacgtgggtattttctgtgtc 3 
II, III 
phsp60 pcDNA3.1 having C. pneumoniae Hsp60 encoding 
insert at EcoRI 
primers: 
F: 5 gctgaattccaccatggcagcgaaaaatatt 3 
R: 5 ccagaattcctagtagtccattcctgcgcttgg 3 
II 
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pSFV4.2 Expression vector Prof. 
Liljeström, 
Karolinska 
Institutet 
pSFV/helperS Vector coding for SFV spike protein Prof. 
Liljeström, KI 
pSFV/helperC Vector coding for SFV capsid protein Prof. 
Liljeström, KI 
pSFV/lacZ pSFV4.2 having E. coli βgal encoding insert Prof. 
Liljeström, KI 
(Chen et al., 
2002) 
pSFV/momp pSFV4.2 having C. pneumoniae MOMP encoding 
insert at BamHI 
primers: as in pmomp 
III 
pSFV/omp2 pSFV4.2 having C. pneumoniae Omp2 encoding 
insert at BamHI  
subcloned from pomp2 
III 
 
Methods used in this project. 
 
Method Described and used in 
Culture conditions 
C. pneumoniae I-IV 
B. subtilis I, IV 
SFV III 
Methods of molecular biology 
RNA and DNA extraction and purification I - IV 
Molecular cloning I - IV 
In vitro transcription III 
PCR, RT-PCR  I - IV 
Transfection II, III 
Expressing recombinant proteins in B. subtilis I, IV 
Expressing recombinant proteins in eukaryotic 
cells II, III 
Affinity chromatography I 
Immunological methods 
Western blot I - IV 
Enzyme Immuno Assays I - IV 
Micro-Immunofluorescence -test I, IV 
Immunofluorescence assays II, III 
Lymphoproliferation assay I, II 
CTL-assay III 
IFN-γ assay III 
Histopathology II 
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Animal work in this project. 
 
Animal work Described and used in 
Production of rabbit sera I 
Mouse infections in vivo I - IV 
Mouse immunizations I, II, III 
Mouse strains  
BALB/c (H2d) I-IV 
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4. Results and discussion 
4.1. Selection of ORFs 
 
The purpose of this project was to design vaccine constructs and regimens for studying 
protective immunity in C. pneumoniae mouse model. In the beginning of this project, only a 
few C. pneumoniae gene sequences were available, and the selection of the candidate 
antigens was mainly based on the published data on human serological response after C. 
pneumoniae infection and the availability of the C. pneumoniae gene sequences in public 
databases. Several C. pneumoniae derived immunogens had been identified by Western 
blotting with human acute and convalescent phase sera. Reactivity of the sera has been seen 
with 98-, 68-, 60-, 54-, 39.5- and 30 kDa proteins (Campbell et al., 1990b; Campbell et al., 
2001; Essig et al., 1999; Freidank et al., 1993; Iijima et al., 1994; Puolakkainen et al., 1995). 
We first selected proteins that were thought to be on the surface of C. pneumoniae EB 
and/or abundantly expressed during infection. Also, earlier observations on immunogenic 
proteins among other chlamydial species, C. trachomatis and C. psittaci were used as 
guidelines. Major outer membrane protein (MOMP, 40 kDa) and a cysteine rich outer 
membrane protein, Omp2 (60 kDa) were chosen for further evaluation as vaccine 
candidates. These proteins are well-characterized antigens among chlamydial species. The 
MOMP is considered a major immunogen in C. trachomatis, but C. pneumoniae MOMP is 
only weakly recognized by human antibodies. In contrast, the Omp2 protein is a strong 
immunogen recognized by antibodies elicited in infections due to all chlamydia species. 
Heat shock proteins appear to play an important role in the pathogenesis of chlamydial 
infection. In several studies, antibodies to C. pneumoniae Hsp60 (GroEL) were associated 
with chronic conditions like arteriosclerosis (Fong et al., 2002b), coronary heart disease 
(Ciervo et al., 2002) and asthma (Huittinen et al., 2001). Consequently, we decided to 
include C. pneumoniae Hsp60 to our panel of antigens and wanted to evaluate whether 
immunization with Hsp60 could induce protection or whether repeated immunizations could 
have an adverse effect by enhancing the immunopathology. 
The C. pneumoniae sequencing project was completed during this study and a great deal 
of new sequence data became publicly available (Kalman et al., 1999; Stephens et al., 
1998). The data revealed a few protein families that we included in our panel of possible 
vaccine candidates: C. pneumoniae polymorphic outer membrane proteins (pmps), proteins 
that are associated with an outer membrane (e.g. TTSS), and proteins that are associated 
with an inclusion membrane (Incs). From the pmp protein family we selected two proteins 
Omp4 (pmp 11) and Omp5 (pmp10) (Knudsen et al., 1999). From the C. pneumoniae TTSS 
proteins we chose a putative lid structure of the secretion system, CopN (= LcrE), whose 
homolog in C. trachomatis was shown to be secreted into inclusion membrane during C. 
trachomatis infection (Fields and Hackstadt, 2000). From the inclusion membrane 
associated protein family we tested C. pneumoniae homologs for IncA, IncB and IncC 
(Subtil et al., 2001).  
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4.2. Production of C. pneumoniae proteins in B. subtilis (I, IV) 
 
To study antigen specific immune responses, we first needed to obtain C. pneumoniae 
proteins that could be used as reagents in immunological assays. For better evaluation, the 
individual antigens should be obtained free from other C. pneumoniae components. 
However, purification of proteins from C. pneumoniae EB is difficult, and to overcome this, 
we chose a Bacillus subtilis heterologous protein expression system (I, IV). A gram-
positive, nonpathogenic bacterium B. subtilis is a suitable host for production of 
heterologous proteins (Himanen et al., 1990; Himanen et al., 1993; Nurminen et al., 1992; 
Puohiniemi et al., 1991). It contains no innate toxins, its cell wall components peptidoglucan 
and teichoic acid are of weak or no biological activity (Himanen et al., 1993). Also, since it 
is gram-positive, it contains no lipopolysaccharide endotoxin. Heterologous proteins can be 
produced as intracellular proteins or they can be secreted out of Bacillus. We chose a use of 
a Bacillus expression vector containing the promoter, a ribosome binding site, and a 
truncated signal sequence of B. amyloliquefaciens α-amylase gene. The use of this vector 
enables high level expression of heterologous proteins, which accumulate into cytoplasm 
(Puohiniemi et al., 1991). 
C. pneumoniae MOMP, Omp2, Omp4, Omp5 and Hsp60 encoding genes extended with 
a histidine hexamer were cloned into a pUB110 derivative plasmid carrying the B. 
amyloliquefaciens α-amylase promoter. All C. pneumoniae proteins were readily expressed 
in B. subtilis. The membrane proteins MOMP-His6, Omp2-His6, Omp4- His6 and Omp5- 
His6 were expressed as inclusion bodies, while Hsp60-His6 was mainly in a soluble form. 
The soluble Hsp60-His6 was purified with affinity chromatography using Ni-NTA resin. 
The insoluble MOMP-His6 and Omp4-His6 were first solubilized with 8 M urea before 
applying to the Ni-NTA column. Proteins were also eluted under denaturing conditions with 
250 mM imidazole in the presence of 8 M urea. The Omp5-His6, however, showed poor 
binding to the nickel column, and was purified after solubilization with SDS and β-
mercaptoethanol by ion exchange chromatography. The Omp2-His6 was also produced in 
Bacillus as insoluble inclusion bodies, and remained insoluble even in 8 M urea. This 
insoluble fraction was actually found to be rather pure preparation of Omp2-His6 (I, Fig. 2). 
All these essentially pure proteins were obtained in milligram quantities.  
Many bacterial membrane proteins produced at high levels in a heterologous host 
accumulate into inclusion bodies. Solubilization and subsequent purification of proteins is 
usually obtained only under strongly denatured conditions. The denatured form of 
recombinant protein sets constraints on the presence of antigenic epitopes found in native 
proteins and must be taken into account when proteins are utilized in different 
immunological assays as antigens.  
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4.3. Utilization of C. pneumoniae recombinant proteins in 
immunological assays (I, IV) 
 
We assessed the use of recombinant C. pneumoniae proteins as reagents to study 
humoral and cellular immunity. The proteins were immunogenic and suitable for production 
of antisera in rabbits. We also characterized murine humoral and cellular responses during 
C. pneumoniae primary and reinfection against several of these recombinant C. pneumoniae 
proteins. 
4.3.1. Assays for CMI 
 
We tested the C. pneumoniae recombinant proteins as reagents to study cell-mediated 
immunity. When used as stimulatory proteins in lymphoproliferation assay, the purified 
protein preparations induced minimal mitogenic activity as shown by relatively low 
background levels observed in proliferative response of naïve or mock-immunized mice (I, 
Fig. 6). When mice were immunized with the proteins or heat-killed whole bacteria, a clear 
increment was detected in proliferative response against the corresponding proteins (I, Fig. 
6). This suggests that the recombinant proteins are useful reagents in studying cellular 
immune responses. In these assays, the denatured state of recombinant outer membrane 
proteins is of less significance; instead the devoid of unspecific stimulatory effects is one of 
the most important advantages. 
4.3.2. Use of recombinant C. pneumoniae proteins in 
characterization of murine systemic and mucosal antibody 
response after infection 
 
Systemic humoral response 
When protein preparations are used to detect specific antibody responses, the 
conformation of the antigen may be critical. The C. pneumoniae recombinant proteins were 
used to develop EIA assays, and the applicability of these assays in detecting humoral 
immune responses during experimental C. pneumoniae infection was evaluated. We 
measured both systemic and mucosal antibody response in mice after C. pneumoniae 
primary and reinfection against five C. pneumoniae recombinant proteins and compared the 
response to that observed against purified C. pneumoniae EB (live or UV-inactivated) (I, 
IV). The mice were intranasally infected once with 106 IFU of C. pneumoniae, and 7-8 
weeks after the primary challenge the mice were reinfected with the same amount of 
bacteria. 
During the experimental infection, C. pneumoniae EB specific serum IgG antibodies 
were detected by EIA 1-2 weeks after infection, and the IgG levels remained elevated at all 
later time points tested (up to 7 weeks after the primary infection). Rechallenge resulted in a 
prompt enhancement of antibody response that lasted up till six weeks after the challenge 
(IV, Fig. 1A). The IgG data by EIA here is in accordance with that of the earlier studies 
using MIF (our unpublished data)(Kaukoranta-Tolvanen et al., 1993). In contrast to IgG 
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response, C. pneumoniae specific serum IgA response was negligible during primary 
infection and only reinfection induced a detectable IgA response, which then quickly 
diminished within one week after the rechallenge (IV, Fig. 1D).  
Sera from infected individuals have earlier been described to recognize several proteins 
of C. pneumoniae (Campbell et al., 1990b). Probably the best-characterized antigen among 
the chlamydial species is the major outer membrane protein, MOMP, which is a major 
immunogen in C. trachomatis. However, in C. pneumoniae infections, human antibodies 
only weakly target the Bacillus-produced MOMP under denaturing conditions (Campbell et 
al., 1990a; Campbell et al., 1990b). Also, in our study the MOMP was weakly reacting with 
antisera from C. pneumoniae infected mice (I, IV). The dissimilar immunological reactivity 
against MOMP proteins of different chlamydial species could be explained by the structural 
differences in their outer membranes. The MOMP may not be a dominant surface protein in 
C. pneumoniae. Also, the antigenic structures in surface exposed epitopes of C. pneumoniae 
MOMP might represent non-linear conformations (Wolf et al., 2001), which are not 
correctly folded in the recombinant, denatured MOMP protein. Indeed, sera either from 
mice immunized with denatured C. pneumoniae (I) or mice infected with C. trachomatis 
MoPn strain (our unpublished data) did respond strongly with the recombinant C. 
pneumoniae MOMP protein. In the C. pneumoniae MOMP, the critical antigenic epitope(s) 
seem to be non-linear, whereas linear epitopes may predominate in the C. trachomatis 
MOMP (Wolf et al., 2001), and therefore, the value of a denatured MOMP antigen in an 
EIA for C. pneumoniae antibodies is limited, although in C. trachomatis infections, it is 
applicable (Puolakkainen et al., 1984). 
In contrast, during experimental infection a strong antibody response was detected 
against Omp2-His6 protein. The antibodies appeared one week after primary infection and 
the levels increased during the reinfection (I, Fig. 4; IV, Fig. 3). Omp2 is also a major 
antigen during human C. pneumoniae infection (Essig et al., 1999; Mygind et al., 1998b). 
The observed strong reactivity of the mouse sera with the Omp2 antigen in EIA suggested 
that, in case of Omp2 recombinant protein, the denatured state does not compromise its use 
in serological assays.  
Antibody response in mice against other studied recombinant proteins, Hsp60-His6, 
Omp4-His6 and Omp5-His6, was negligible after primary infection. However, immediately 
after rechallenge Hsp60 specific antibodies appeared and Hsp60 was shown to be a major 
immunogen during the reinfection in mice (I, Fig. 4; IV, Fig. 3A). High chlamydial Hsp60 
antibody titers in humans are often observed in chronic conditions (Betsou et al., 2003; 
Debattista et al., 2003; Eckert et al., 1997; Fong et al., 2002b; Huittinen et al., 2001). 
Indeed, determination of antibodies to chlamydial Hsp60 has proven valuable in 
seroepidemiological studies, while occurrence of the Hsp60 antibodies in various chronic 
conditions and the wide cross-reactivity limit the use of Hsp60 in diagnosis of acute C. 
pneumoniae infection. 
Interestingly, the systemic antibody response against the two selected Pmp family 
proteins, Omp4 (Pmp 11) and Omp5 (Pmp 10), was nil also after reinfection in mice (IV, 
Fig. 3B). It has been suggested that the polymorphic membrane proteins may cover the C. 
pneumoniae outer membrane as surface layer proteins (Knudsen et al., 1999), and they 
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would probably mask for example the MOMP porin protein. Therefore, we expected, that 
the Pmps were an optimal target for antibody recognition on the surface of bacteria. 
However, our panel consisted of only two out of 21 representatives of C. pneumoniae Pmp 
family, and there are at least three other Pmp proteins that have later been documented to be 
on the surface of C. pneumoniae (Vandahl et al., 2002). Also, differential expression of Pmp 
proteins, especially Omp5 protein (pmp 10) is well documented (Birkelund et al., 1998; 
Pedersen et al., 2001; Vandahl et al., 2002). This could suggest, that not all Pmp proteins are 
produced during C. pneumoniae infection. According to our studies, the lack of anti-Omp5 
response during both primary and reinfection could suggest that Omp5 protein expression is 
shut off. However, we cannot rule out with certainty, that the Omp5 specific antibodies in 
the infected individuals cannot be detected using a denatured antigen.  
 
Mucosal antibody response 
The ability of recombinant C. pneumoniae proteins to detect antibodies in mucosal 
secretions (ie. broncho alveolar lavage (BAL) samples) was evaluated in this study, and the 
results were compared to those obtained using purified C. pneumoniae EB (live or UV-
inactivated).  
Although no serum IgA response was seen during the primary infection, the C. 
pneumoniae EB specific mucosal IgA response was instead readily detected in BAL 
secretions of the infected mice. Also, after rechallenge a prompt and enhanced response 
became evident (IV, Fig. 2). There was an inverse correlation between the levels of mucosal 
IgA antibodies and the pulmonary bacterial counts in the infected mice. Within the first days 
of infection, the bacterial counts were high, and secretory IgA levels were undetectable. As 
the IgA levels in mucosal secretions increased as a function of time, the bacterial load 
started to diminish. However, the association of high levels of IgA antibodies with bacterial 
clearance does not directly suggest a role for mucosal IgA response in protection. The 
production of IgA antibodies may only reflect the existence of a priming antigen in the 
infected individual, and as soon as the antigen (or at least most of the bacteria) is cleared, 
the relatively short-lived IgA antibodies are vanished. On the other hand, local antibodies 
have shown to have important role in protection against C. trachomatis (Moore et al., 2002; 
Moore et al., 2003). Therefore, defining the antigen specificity of the mucosal IgA antibody 
response could provide additional information to be used in the vaccine development 
against chlamydial infection.  
The secretory IgA antibodies in the mucosal secretions are involved in inhibition of 
adhesion of the microbes to their host cells, and they obviously recognize surface structures 
of the microbes. Interestingly, secretory IgA antibodies from C. pneumoniae infected mice 
showed different antigen specificity during the primary infection than circulating antibodies 
in the blood. The only antigen of our five-protein panel (MOMP, Omp2, Hsp60, Omp4 and 
Omp5) that was recognized by IgA antibodies in BAL was Omp4 (IV, Fig. 4B), whereas 
Omp2 was the main antigen reacting with serum antibodies (IV, Fig. 3A). However, after 
reinfection the production of Omp2 and Hsp60 specific mucosal IgA antibodies were also 
induced in addition of Omp4 response (IV, Fig. 4B). Interestingly, the early-phase IgA 
antibodies after C. trachomatis genital infection are directed to the MOMP protein of C. 
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trachomatis and later the reaction to 62 kDa protein is also noted (Ramsey et al., 1989). 
During C. pneumoniae primary and reinfection BAL IgA antibodies reacted only weakly 
against MOMP. This result could suggest the prominent role of Omp4 protein in C. 
pneumoniae infection as a target for neutralizing action by the host. The differential antigen 
specificity of mucosal antibodies during acute and reinfection to some of these key 
antigens in C. pneumoniae could potentially be exploited in developing diagnostic 
serological assays.  
The purification of outer membrane proteins (MOMP, Omp2, Omp4, and Omp5) 
produced in B. subtilis was feasible only in denaturing conditions. This may set constraints 
on the applicability of the antigens in some immunological assays, especially when humoral 
response is studied. However, denatured C. pneumoniae recombinant membrane proteins 
are the only form of purified proteins available. On the other hand, after infection, it is likely 
that the antibodies elicited presumably react both with linear and non-linear epitopes of the 
antigens, and therefore also selected denatured antigens can be utilized in diagnostic 
enzyme-immuno assays.  
4.4. DNA immunization against C. pneumoniae in mice (II) 
 
In this project, we characterized the immune response to C. pneumoniae proteins in 
BALB/c pulmonary murine model (Penttila et al., 1998a; Penttila et al., 1998b; Penttila et 
al., 1999) after different immunization strategies and assessed the protective effect of these 
immunizations against intranasal challenge infection (II, III). In the immunization studies, 
the initial aim was to induce cell-mediated immune response in mice, especially Th1 type 
immunity characterized by IFN-γ production and CD8+ T cell activity. To obtain these 
wanted responses, we chose DNA immunization and viral vector immunization strategies. 
Naked DNA plasmids or recombinant Semliki Forest virus vectors were tested alone or 
combined in heterologous prime-boost regimen. The DNA immunization was initially used 
for screening antigens that would afford best protection in our infection model. From the 
different selected C. pneumoniae genes the best protection or strongest immune responses 
were seen with DNA constructs expressing MOMP, Omp2 or Hsp60 proteins. The summary 
of DNA immunization experiments published in paper II is shown in table 2. 
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Table 2. DNA immunization experiments (II) 
 
Eukaryotic 
expression 
vector 
C. 
pneumoniae 
antigens 
In vitro 
expression in 
COS7 cells 
Mouse 
immunization 
scheme 
Results 
pcDNA3.1 
(Invitrogen®) 
MOMP negligible 3ximm. (i.m.)  
in 3wk intervals; 
challenge 2wk 
after the last 
immunization 
Partial protection 
against intranasal 
challenge;  
No ab response, 
MOMP specific 
CMI (splenocyte 
proliferation) 
-- Omp2 strong -- No protection 
against challenge; 
Strong ab response, 
CMI negligible 
(splenocyte prolif.) 
-- Hsp60 strong -- Partial protection 
against challenge; 
Ab response only 
after challenge, 
Hsp60 specific CMI 
(splenocyte prolif.) 
 
4.4.1. In vitro protein expression 
 
The expression of recombinant proteins was first confirmed by transfecting the 
constructs into COS-7 cells, and assessing the expression by IFA or Western blotting. 
Generally, the C. pneumoniae proteins were readily detected in the COS-7 cells, but the 
expression of MOMP protein in eukaryotic cells was poor (II, Fig. 1). For example, 
overexpression of recombinant C. trachomatis and C. psittaci MOMP proteins is toxic in the 
E. coli expression systems (Dascher et al., 1993; Koehler et al., 1992). Equally, we assume, 
that the expression of C. pneumoniae MOMP in the mammalian cells after transfection may 
not be optimal, and probably only low level of antigen is presented in the transfected host 
cells. For example, expression of bacterial genes in mammalian cell may be difficult 
because of the differences in the DNA codon usage for the same amino acids. For some 
bacterial codons, which are rare in mammalian cells there is also limiting amounts of tRNA 
available and a risk for producing truncated translation products is evident (Bergmann-
Leitner and Leitner, 2004).  
If the expression level of the full-length protein is low, because of its toxicity, an 
expression of partial protein could be successful. The DNA vaccine could consist only of 
short DNA sequences (= minigenes) that correspond for example to immunogenic CD8+ 
and/or CD4+ T cell epitopes of the protein. In this work, we constructed a polytope DNA 
vaccine that consisted only of repeated short DNA sequences of two predicted C. 
pneumoniae MOMP CD8+ epitopes (Saren et al., 2002) in tandem. However, these 
minigene vaccines were poorly immunogenic in mice, and this research approach was not 
further pursued (data not shown).  
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4.4.2. Immune response to immunization 
 
For immunizations, the cloned expression vectors were cultured in large-scale in E. coli 
and were purified from bacterial cultures by endotoxin-free plasmid purification kit and 
dissolved in saline buffer. Mice were immunized intramuscularly (i.m.) with naked DNA 
constructs three times at three weeks intervals, and two weeks after the last immunization, 
the mice were intranasally challenged with C. pneumoniae. Both humoral and cell-mediated 
immune responses to C. pneumoniae proteins were measured two weeks after the last 
immunization before the challenge.  
After pomp2 immunizations, all mice developed strong systemic antibody response 
against the Omp2 protein. This is accordance with the earlier data from studies on infection 
kinetics in mice (I, IV) and with human serological data showing that Omp2 is a strong 
immunogen recognized by antibodies after C. pneumoniae infection (Campbell et al., 
1990b; Mygind et al., 1998b). However, MOMP and Hsp60 proteins encoding constructs 
did not elicit such a serological response in mice after immunizations  not even after 
multiple boosting injections.  
One reason for our inability to detect MOMP antibodies is likely the low expression 
level of MOMP antigen in mouse cells after DNA immunization. It is generally believed, 
that high level expression of antigen after DNA vaccination correlates with the magnitude of 
humoral immune response generated (Gurunathan et al., 2000). Direct generalization of the 
magnitude of immune response versus antigen expression is difficult, the correlation may 
not be linear. Also, there are differences between antigens and infection models in ability to 
induce strong antibody responses or cellular immunity. After C. pneumoniae infection in 
mice, the antibodies against MOMP do not raise as soon as antibodies against the major 
immunogen Omp2, and it possibly that the MOMP antibody response only appeared later 
than 10 days after challenge (I, IV).  
Although, there were no problems in expressing the recombinant C. pneumoniae Hsp60 
in eukaryotic cells, multiple injections of recombinant DNA did not induce antibody 
response in immunized mice. However, after the challenge immunized mice developed 
quickly anti-Hsp60 antibody response, indicating that they had been primed with the 
antigen.  
After DNA immunization, cellular immune response was demonstrated as protein 
specific proliferation of splenocytes of mice immunized with the MOMP or Hsp60 
expressing DNA vaccine (II, Fig. 2). However, the proliferative activity of splenocytes from 
pomp2 immunized mice was negligible, although an induction of Omp2 specific antibodies 
in these mice indicated successful priming by the vaccine constructs. In addition to the 
proliferative activity, the splenocytes of immunized mice showed CTL activity. The activity 
was seen against two predicted CD8+ epitopes: 7205 (H-2d, RGNSTAFNL) in MOMP and 
8511 (H-2d, CYGRLYSVKV) in Omp2 after immunization with DNA vectors coding for 
MOMP and Omp2, respectively (unpublished data).  
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4.4.3. Response to challenge 
 
As shown above, DNA constructs did induce protein specific humoral and cell-mediated 
immunity, but the more important question in screening possible vaccine candidates was, 
whether the antigen could induce protection against C. pneumoniae challenge. The 
immunized mice were challenged intranasally with 1 x 106 IFU of C. pneumoniae. Ten days 
after the challenge, protection was evaluated by culturing the supernatants of the collected 
lung homogenates. The best protection was seen in mice immunized with MOMP or Hsp60 
expressing constructs, also these mice showed the most prominent proliferation responses 
and weak antibody response after immunizations (II, Fig. 3). The reduction in the mean IFU 
counts was approximately 1.2-1.5 log.  
In several other studies, a partial protection against the C. pneumoniae infection has 
been observed in mice vaccinated with naked DNA carrying genes for major outer 
membrane protein (MOMP), 60 kD heat shock protein (Hsp60) or ADP/ATP translocase 
(Npt1Cp) (Murdin et al., 2000; Svanholm et al., 2000). However, so far DNA immunizations 
have reduced the lung bacterial burden only modestly (1.0  1.2 log), which is at best 
comparable to the protection seen after primary C. pneumoniae infection in mice. In 
contrast, in another murine Chlamydia model, respiratory infection due to C. trachomatis 
mouse pneumonitis (MoPn) biovar, DNA vaccines coding for C. trachomatis MOMP have 
been shown to reduce the peak growth of bacteria by >100-fold upon challenge. The 
vaccinated mice developed cellular and humoral immune responses suggestive of Th1 type, 
shown as lymphocyte proliferation with IFN-γ production and a serum antibody responses 
mainly IgGa (Zhang et al., 1997; Zhang et al., 1999). However, DNA vaccination (i.m.) 
with C. trachomatis MOMP coding constructs failed to protect against C. trachomatis 
genital infection model (Pal et al., 1999), which probably reflects different requirements for 
protective immunity in pulmonary and genital infection models.  
4.5. DNA priming and rSFV boosting (III) 
 
To induce more potent immune responses we used recombinant viral vectors as 
vaccines. Recombinant live alphavirus vaccines are effective in delivering RNA of interest 
into eukaryotic cells [reviewed by (Lundstrom, 2001; Tubulekas et al., 1997)]. Vaccines 
based on the recombinant self-replicating alphavirus, Semliki Forest virus (SFV), induce a 
strong humoral and cellular immune response with apparent long memory (Zhou et al., 
1995).  
The SFV vector system includes a recombinant DNA plasmid, coding for the desired 
foreign gene and replicase with a packaging signal, and two different helper DNA plasmids 
coding for the viral structural proteins (Fig. 4). The recombinant virus particles are formed 
by co-transfecting in vitro transcribed recombinant RNAs from the three plasmids into the 
cultured cells. The replication of transfected RNAs as well as the expression of the proteins 
encoded by the genes of the vectors eventually leads to a formation of recombinant virions 
containing only the genomic RNAs expressing the gene of interest (Smerdou and 
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Liljestrom, 1999). These recombinant viral particles can then be used as so called suicidal 
vaccines. When the vaccine is administered to animals, the virus infects the cells and 
express protein encoded by its genomic RNA (in this case only the gene of interest).  In the 
absence of RNAs for structural proteins, no new viruses are synthesized in the immunized 
individual. Due to wide host range of SFV, efficient delivery of recombinant RNA is 
achieved after recombinant virus infection (or immunization).  
We also wanted to study the effect of prime-boost technique on enhancing the protective 
immunity. Especially, priming first with naked DNA and boosting with a viral vector 
expressing the same antigen has generated higher levels of immune responses in many 
infectious models (e.g. malaria, influenza) (Degano et al., 1999; Schneider et al., 1998). The 
prime-boost technique has resulted in antigen specific antibody production predominantly of 
the IgG2a isotype and IFN-γ secreting CD8+ T cells that are associated with the 
development of Th1-type immunity (Schneider et al., 1998). In table 3 is summary of the 
viral vector immunizations and prime-boost immunizations published in paper III. 
 
 
Table 3. SFV immunization and prime-boost immunization experiments (III). 
 
Expression 
vector 
C. 
pneumoniae 
antigens 
In vitro 
expression in 
BHK-21 cells 
Mouse 
immunization 
scheme 
Results 
SFV immunization: 
pSFV4.2  
(P.Liljeström) MOMP moderate 
2ximm. (s.c.)  
in 2wk intervals; 
challenge (i.n.) 1wk 
after the last 
immunization 
Decrement of bacterial 
load in the lungs;  
No ab response, 
specific CMI (IFN-γ & 
CTL) 
-- Omp2 strong -- 
No protection against 
challenge; 
Strong ab response, 
Specific CMI (IFN-γ & 
CTL) 
Prime-boost immunization: 
pcDNA3.1 + 
pSFV4.2 MOMP  
DNA 2ximm. (i.m.), 
rSFV 1ximm. (s.c.)  
in 3wk intervals; 
challenge 2wk after 
the last 
immunization 
Decrement of bacterial 
load in the lungs; 
No ab response,  
specific CMI (IFN-γ & 
CTL) 
-- Omp2  -- 
Partial protection 
against challenge; 
Strong ab response, 
Specific CMI (IFN-γ & 
CTL) 
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4.5.1. In vitro protein expression 
 
We cloned different C. pneumoniae outer membrane proteins, MOMP and Omp2 into 
SFV expression vectors, pSFV4.2, which carries a deletion in the coding region for viral 
structural proteins. C. pneumoniae recombinant proteins were readily expressed in BHK-21 
cells that had been transfected with in vitro transcribed recombinant RNA or infected with 
recombinant SFV particles. However, the expression levels of C. pneumoniae specific 
proteins were lower than control protein β-galactosidase (βgal) as was shown by Western 
blotting (III, Fig. 1). This was not surprising, since the expression of outer membrane 
proteins in mammalian cells, especially MOMP protein, was expected to raise difficulties in 
the light of our earlier experience with DNA constructs. However, the MOMP protein 
expression was actually found to be quite moderate compared to a scant expression from the 
recombinant pcDNA3.1 constructs.  
4.5.2. Immune response to immunization 
 
The viral delivery vehicles, recombinant SFV particles were prepared for the 
immunization as follows. BHK-21 cells were co-transfected with in vitro transcribed RNA 
carrying the chlamydial gene of interest, and the two helper-RNAs carrying the genes for 
viral structural proteins (spiking and core proteins). After 24-48h incubation the assembled 
viruses were harvested from the growth medium by ultracentrifugation. 1x106 infectious 
units (IU) of recombinant SFV particles in 100µl saline buffer were injected subcutaneously 
(s.c.) into BALB/c mice two times at 2 weeks interval. Recombinant SFV particles 
expressing βgal protein were used as a control (Chen et al., 2002). In the prime-boost 
immunization, the mice were first given DNA twice (i.m.) and then boosted with 1 dose of 
recombinant SFV particles (s.c.). Two weeks after the last immunization, cell-mediated 
immune response (CMI) was evaluated from the spleens and sera were taken for antibody 
detection. 
Isolated splenocytes from SFV immunized mice showed already without any stimulation 
such a strong unspecific proliferation activity that antigen-specific reactions could not be 
detected. However, splenocytes of MOMP and Omp2 immunized mice responded to 
stimulation with corresponding protein and also with inactivated C. pneumoniae EBs by 
secreting higher amounts of IFN-γ as compared to the control mice (III, Table 1). In 
addition to IFN-γ production, the splenocytes of immunized mice showed CTL activity. The 
activity was seen against CD8+ epitopes 7205 (H-2d, RGNSTAFNL) in MOMP and 8511 
(H-2d, CYGRLYSVKV) in Omp2 after immunization with SFV constructs coding for 
MOMP and Omp2, respectively (III, Fig. 2). Interestingly, our previous results have shown 
that immunization with naked DNA construct coding for MOMP or Omp2 induced CTL 
response exactly against the same epitopes (unpublished data). It seems, that both antigen 
delivery systems (naked DNA and recombinant SFV) lead to similar processing and 
presentation of CD8+ epitopes with MHC-I for an antigen-specific CD8+ T cell response. 
The unspecific proliferation activity was linked to the boosting effect of SFV particles, since 
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unspecific proliferation activity was not seen when mice were first primed with DNA and 
then boosted SFV particles only once. The prime-boost immunization induced significant 
antigen-specific proliferation response as well as IFN-γ production in the isolated 
splenocytes compared to the control mice (III, Table 1). 
Both rSFV immunizations and DNA priming-SFV boosting led to similar systemic 
humoral response against the corresponding proteins than was observed earlier in our DNA 
immunization experiments. Again, the Omp2 coding constructs elicited in mice a strong 
specific antibody response, whereas mice that were immunized with MOMP coding 
constructs did not induce protein specific antibody production after immunization. As was 
already discussed earlier, the undetectable MOMP response after immunizations could be 
due to low levels of produced antigen in the immunized mice. On the other hand, 
recombinant SFV constructs were able to express moderate levels of recombinant MOMP 
protein in vitro compared to almost undetectable production from the recombinant 
pcDNA3.1 constructs.  
In this study, we also analyzed IgG isotype response from sera of immunized mice. The 
two immunization methods differed in their ability to induce IgG2a antibodies. The prime-
boost technique was inducing both IgG1 and IgG2a isotypes, but after SFV immunizations 
only IgG1 response was detected. 
4.5.3. Response to challenge 
 
Two weeks after the last immunization mice were challenged intranasally with 106 IFUs 
of C. pneumoniae EBs. Ten days after the challenge, a microbiological protection was 
assessed by measuring IFU counts from the supernatant of homogenized lung samples. At 
the same time-point, immune responses from spleens, mediastinal lymph nodes (mLN) and 
lungs, as well as specific antibodies from sera were analyzed.  
Neither of the immunization strategies could induce sterilizing immunity against 
challenge, but in some immunization groups significant reduction in the bacterial load in the 
lungs was achieved (III, Fig. 3). The best protection was seen in the mice that were primed 
first with DNA and then boosted with SFV. Although only Omp2 expressing construct was 
offering statistically significant protection, also MOMP expressing construct showed a 
similar trend. In some mice the protection was notable, although in the group there was a 
considerable variation in the pulmonary culture results between the individual mice. Mice 
that were vaccinated only with viral particles expressing MOMP antigen showed also 
significant decrement of bacterial load in their lungs.  
The local IFN-γ production of the cells isolated from the mediastinal lymph nodes and 
pulmonary cells of the immunized and challenged mice was very low in mice that were 
immunized only with viral particles. Instead after prime-boost immunization, the secretion 
of IFN-γ by the cells isolated from mediastinal lymph nodes or lungs was significant 
compared to the control mice. A strong IFN-γ response at the site of infection in DNA/rSFV 
immunized mice and a strong serum IgG2a response detected in these mice after 
immunization could suggest induction of a more Th1 biased immune response.  
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The use of other viral or bacterial vectors as delivery vehicles has been applied to 
chlamydial infection models. Igietsemes group found that recombinant Vibrio cholerae 
ghosts expressing MOMP gene gave a partial protection against genital challenge of C. 
trachomatis in mice (Eko et al., 2003). Murdin et al. have also demonstrated poliovirus 
hybrids expressing variable epitopes of C. trachomatis MOMP to elicit antibodies that were 
able to neutralize C. trachomatis infectivity both in vitro, for cell cultures, and passively in 
vivo, for conjunctival epithelia for cynomolgus monkeys (Murdin et al., 1993; Murdin et al., 
1995). Viral vectors have a very attractive facility in that they possess a strong adjuvant 
property. Many viruses induce apoptosis and viral structural proteins stimulate host cells to 
secrete proinflammatory cytokines. This assures a prominent activation of innate immune 
response, which is the prerequisite for an antigen-specific acquired immunity (Bergmann-
Leitner and Leitner, 2004).  
Especially, the prime-boost techniques involving different recombinant vectors coding 
for same antigen have been efficient in inducing cell-mediated immunity (Ramshaw and 
Ramsay, 2000). In C. trachomatis MoPn infection model, priming with MOMP DNA 
followed by MOMP ISCOM (immune response stimulating complex) boosting gave 
enhanced protection against pulmonary challenge compared to the protection detected after 
DNA immunization or after immunization with MOMP+ISCOM alone. Also, this protection 
was almost as efficient as that induced by live organisms (Dong-Ji et al., 2000). Enhanced 
protection correlated with stronger delayed-type hypersensitivity, higher levels of IFN-γ, 
and increased IgA responses in lung homogenates.  
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4.6. Why only partial protection was achieved? 
 
Although, the vaccination results and findings are very important and interesting, the 
data have also been disappointing: the observed protection after DNA or viral vaccination 
has been at best only comparable to the protection seen after infection. To successfully 
continue vaccine development, one clearly needs to learn more on correlates of protection in 
C. pneumoniae infections and on the immunogenic structures of the bacteria. The afore-
mentioned techniques specifically induced a strong cell-mediated response characterized by 
IFN-γ production at the site of infection. However, the components of the protective 
immunity have been deduced from studies using the experimental acute infection models, 
and they may well represent the immune response needed for the seemingly successful 
eradication (by culture) of the microbe, but they could also lead to coexistence of the 
pathogen within the host (persistence). It is not known, how acute infection could be 
eradicated for good, and much less is known about the mechanisms needed to eradicate 
persistent infection. In vitro studies, focusing on chlamydial developmental cycle have 
suggested several cellular mechanisms, how chlamydia could evade the immune response 
and promote persistence: 
- Intracellular Chlamydia can evade humoral neutralizing antibody response 
- Chlamydia can make itself silent to immune cells inside the infected cell 
by inhibiting phagolysosomal fusion and minimizing antigen presentation. 
- Chlamydia can resist apoptosis of the host cells and/or induce apoptosis of 
immune cells and thus promote survival and avoidance of cytotoxic effect 
 
Evasion of neutralizing antibodies 
In several in vitro studies monoclonal antibodies generated against the MOMP protein 
have been shown to neutralize C. trachomatis infectivity in cell cultures (Peterson et al., 
1991; Su and Caldwell, 1991). Similar neutralizing antibodies against C. pneumoniae have 
only recently been characterized (Puolakkainen et al., 1995; Wolf et al., 2001). However, 
both Chlamydia species show also antigenic variation in their surface structures that may 
assist Chlamydia to evade antibodies. C. trachomatis shows considerable variation in its 
MOMP protein between serovars and C. pneumoniae expresses differentially its 
polymorphic outer membrane proteins during the infection (Knudsen et al., 1999).  
The extracellular EB form of chlamydia, is taken into the cells very quickly (Byrne and 
Moulder, 1978), thereby diminishing the possibility of neutralizing antibodies to act against 
the bacteria. Once inside the host cells, chlamydia is protected against the neutralizing 
defence mechanisms of antibodies.  
However, according to in vitro studies, antibodies may also have an essential role in 
protective immunity. Opsonization is one mechanism how antibodies could mediate anti-
chlamydial activity by their host (Moore et al., 2002). Opsonized chlamydiae have been 
shown efficiently phagocytosed by macrophages or polymorphonuclear cells and be 
destroyed. Also, opsonized chlamydiae are efficiently in vitro ingested inside antigen 
presenting cells (APC; i.e. macrophages and dendritic cells) via FcR mediated endocytosis. 
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These cells are able to induce naïve T cells or boost activated T cells for a Th1 type 
response e.g. for IFN-γ production. Addition to neutralization and opsonization, antibodies 
may act through antibody dependent cellular cytotoxicity (ADCC), where antibodies first 
bind to the specific antigen on the infected host cells that express chlamydial antigens on 
their surface. Cytotoxic effector cells ie. macrophages and natural killer (NK) cells then 
recognise bound antibodies via their FcR. Moore et al. (Moore et al., 2002) showed that the 
presence of anti-chlamydia antibodies indeed increased macrophage killing activity against 
chlamydia-infected epithelial cells.  
 
Silent survival inside the host cell 
The internalized vesicles, containing the infectious chlamydial EB, are able to inhibit 
normal endocytic vesicle trafficking that leads to fusion with lysosomes. A very early event 
of the inhibition does not probably need chlamydial gene expression. Chlamydia, which 
protein synthesis has been inhibited, or internalized preparations of chlamydial cell wall are 
also able to inhibit phagolysosomal fusion (Hackstadt, 1999; Scidmore et al., 1996). After 
internalization phase, the nascent inclusions are modified in such a way that they do not fuse 
with the endocytotic vesicle system. Instead, they are directed to the peri-Golgi region and 
become associated with exocytotic vesicles. The chlamydial counterparts that play an active 
role in modification of inclusion membrane are still unknown, but some Chlamydia-specific 
inclusion membrane proteins (Incs) have been recognized (Hackstadt, 1999; Rockey and 
Rosquist, 1994; Stephens et al., 1998).  
Although chlamydia is living strictly inside the inclusion, it probably secretes proteins 
outside the vesicle into host cytoplasm, where they can be degraded and subsequently 
presented on the MHC-molecules. However, chlamydia may shut down this antigen 
presentation in its host. Chlamydial proteosome-like activity factor (CPAF) has been 
identified in both C. trachomatis and C. pneumoniae infected cells (Fan et al., 2002; Zhong 
et al., 2001). It degrades the host transcription factor, RFX5 required for expression of host 
class I and II major histocompatibility antigens (MHC). CPAF is secreted into the host 
cytoplasm and it is not found from the chlamydia organisms itself, suggesting that the main 
task for the protein is just to manipulate host cell. The CPAF gene has not been found to 
show significant homology with known genes of other bacteria but show significant 
homology among Chlamydiae (Zhong et al., 2001). According to these studies, this could be 
a mechanism how chlamydia escapes recognition by cellular immune system and therefore 
be also a key mechanism for cellular persistence (Fan et al., 2002; Zhong et al., 2001). 
However, the exact mechanism how CPAF works precisely and how would the mechanism 
work inside the APC is not known. 
 
Modulation of apoptosis 
One form of silence for intracellular microbes is their ability to resist host cell apoptosis, 
programmed cell death. Apoptosis is one of the key mechanisms of host to expose 
intracellular microbes to the phagocytes or antigen presenting cells (APC) that initiate the 
subsequent specific anti-microbial immune response. As an obligate intracellular pathogen, 
chlamydia must resist host cell apoptosis at least the time that is required for its 
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developmental cycle to be completed (Hackstadt, 1999). Both C. pneumoniae and C. 
trachomatis have been shown to resist apoptosis in epithelial cells and macrophages or in 
HeLa cells (Airenne et al., 2002; Carratelli et al., 2002; Fan et al., 1998). The antiapoptotic 
capacity is dependent on chlamydial protein synthesis. Interestingly, C. psittaci has, in 
contrast, shown to induce apoptosis both in HeLa and murine macrophage cell lines (Ojcius 
et al., 1998). The precise models how these both controversial mechanisms could be 
involved chlamydial infections in vivo are speculative, but they both could be relevant. 
Antiapoptotic mechanisms could be important in order to evade immune responses and 
survive silently in side the cells. On the other hand, as soon as new infectious progeny is 
ready to infect new cells, it could be microbes advantage to be an undercover passenger 
inside the apoptotic vesicles and travel into new cells e.g. macrophages.  
Taken together, these mechanisms of intracellular silence may be very efficient features 
for chlamydia to resist hosts cell-mediated immunity. They may be a partial explanation for 
disappointing results observed in many recent immunization studies, where animals have 
been immunized with vaccines that specifically induce Th1 biased cell-mediated immunity. 
In recent Chlamydia immunization studies, the strategy has been again immunize mice with 
the proteins, but this time together with strong adjuvant inducing potent CMI or/and 
mucosal responses (e.g. CpG motifs or cholera toxin, respectively) in order to induce a more 
versatile immunity (Berry et al., 2004; Pal et al., 2002; Pal et al., 2003). 
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5. Concluding remarks and future prospects 
 
Studies using animal models of C. pneumoniae infection have shown that cell-mediated 
immunity is necessary for protection against the infection in mice. More specifically, CD8+ 
T cells and IFN-γ have shown to be important effectors mediating the protection both in 
primary and reinfection of C. pneumoniae, suggesting an essential role for Th1 type 
immunity in protection. Immunization with naked DNA has been used to induce Th1 type 
immunity against C. pneumoniae. A partial protection has been observed in mice vaccinated 
with naked DNA coding for proteins major outer membrane protein (MOMP), 60 kDa Heat-
shock protein (Hsp60) or ADP/ATP translocase (Npt1Cp) (II)(Murdin et al., 2000; 
Svanholm et al., 2000). However, so far DNA immunizations have reduced the lung 
bacterial burden only modestly (1.0  1.2 log), which is at best comparable to the protection 
seen after primary C. pneumoniae infection in mice.  
DNA vaccines have been suggested to express too low levels of antigen, and therefore 
more efficient antigen delivering system has been developed. Especially, the prime-boost 
techniques involving different recombinant vectors coding for same antigen have been 
efficient in inducing cell-mediated immunity. In our hands, the prime-boost technique 
induced immune response characterized with local IFN-γ production by pulmonary and 
mLN cells, as well as a strong IgG2a response in serum, but did not afford better protection 
upon challenge than was seen after DNA immunization alone (II, III). 
Of course, an ultimate goal is a vaccine that could offer sterilizing and long-lasting 
immunity against chlamydial infection. To successfully continue vaccine development, one 
clearly needs to learn more on correlates of protection in C. pneumoniae infections and on 
the immunogenic structures of the bacteria. However, in chlamydial infection, where 
bacteria alternate between intracellular and extracellular stages, the immune system may 
have to mobilize a wide range of effector mechanisms that could target the pathogen both 
outside and inside the host cell. For example, the role of mucosal antibodies in protection 
against C. pneumoniae infection is poorly studied. Especially, the possible role of antibodies 
targeting the polymorphic membrane proteins on the surface of C. pneumoniae warrants 
further study both in animal models as well as in humans (IV).  In addition, different 
immune responses may be needed in different stages of the infection (acute infection vs. 
established/persistent infection; actively replicating chlamydia vs. latent chlamydia; 
chlamydia inside a macrophage vs. chlamydia inside an epithelial cell, etc.). The immune 
response developed during the acute infection may not be optimally effective for clearance 
of infection and prevention of pathologic sequelae, although the effector mechanisms 
protective against acute infection may well be partly protective also against persistent 
infection. The immunity may be directed towards C. pneumoniae antigens that are not 
expressed or presented during persistent infection, or the needed/optimal effector functions 
may not be stimulated strongly enough. In our future vaccine prospects, we want to study 
especially those antigens that are relevant during established, persistent C. pneumoniae 
infection, and use them as therapeutic vaccines to provide for bacterial clearance. 
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